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Bicyclic (galacto)nojirimycin analogues as glycosidase inhibitors: Effect of
structural modiﬁcations in their pharmacological chaperone potential towards
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A molecular-diversity-oriented approach for the preparation of bicyclic sp2-iminosugar glycomimetics
related to nojirimycin and galactonojirimycin is reported. The synthetic strategy takes advantage of the
ability of endocyclic pseudoamide-type atoms in ﬁve-membered cyclic iso(thio)ureas and guanidines to
undergo intramolecular nucleophilic addition to the masked carbonyl group of monosaccharides. The
stereochemistry of the resulting hemiaminal stereocenter is governed by the anomeric effect, with a
large preference for the axial (pseudo-a) orientation. A library of compounds differing in the
stereochemistry at the position equivalent to C-4 in monosaccharides (D-gluco and D-galacto), the
heterocyclic core (cyclic isourea, isothiourea or guanidine) and the nature of the exocyclic nitrogen
substituent (apolar, polar, linear or branched) has been thus prepared and the glycosidase inhibitory
activity evaluated against commercial glycosidases. Compounds bearing lipophilic substituents behaved
as potent and very selective inhibitors of b-glucosidases. They further proved to be good competitive
inhibitors of the recombinant human b-glucocerebrosidase (imiglucerase) used in enzyme replacement
therapy (ERT) for Gaucher disease. The potential of these compounds as pharmacological chaperones
was assessed by measuring their ability to inhibit thermal-induced denaturation of the enzyme in
comparison with N-nonyl-1-deoxynojirimycin (NNDNJ). The results indicated that amphiphilic
sp2-iminosugars within this series are more efﬁcient than NNDNJ at stabilizing b-glucocerebrosidase
and have a strong potential in pharmacological chaperone (PC) and ERT-PC combined therapies.
Introduction
Sugarmimics bearing endocyclic nitrogen atoms (iminosugars and
azasugars), such as deoxynojirimycin (DNJ) 1 and castanosper-
mine 2, have been shown to behave as potent glycosidase inhibitors
(Fig. 1). Given the broad range of biological and pathological
processes in which glycosidases are involved, from the catabolism
of sugars to the biosynthesis of the complex oligosaccharide
chains in glycoproteins and glycolipids, speciﬁc inhibitors of
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Fig. 1 Structures of DNJ (1), castanospermine (2), and the bicyclic
nojirimycin analogues 3–10.
these enzymes bear strong potential for the development of
new pharmaceuticals1 e.g., in the treatment of type II diabetes
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mellitus,2 viral infections,3 cancer4 or hereditary enzyme deﬁciency
diseases.5
Despite their promise, neither 1 or 2 nor other members of this
family of glycomimetics have realized their full clinical potential.
This is largely because of a lack of commercially viable syntheses
and difﬁculties in preparing a comprehensive palette of variant
structures. Moreover, in most cases the lack of speciﬁcity between
different isoenzymes represents an important problem for clinical
applications. In order to tackle the problems of enzyme selectivity,
several years ago we developed a new family of glycomimetics
in which the amine-type nitrogen characteristic of iminosugars
was replaced by a pseudoamide-type nitrogen atom with high sp2-
character (sp2-iminosugars; e.g. compounds 3 and 4).6 This struc-
turalmodiﬁcationprofoundly alters the stereoelectronic properties
at the pseudoanomeric region, rendering compounds that are
chemically, conformationally and conﬁgurationally stable in water
solution even when incorporating oxygen (hemiaminals), nitrogen
(gem-diamines) or sulfur substituents (aminothioacetals) at the
position equivalent to C-1 in monosaccharides.7 For instance, the
pseudoanomeric hydroxyl group in the cyclic carbamate nojir-
imycin derivative 3 was found exclusively in the axial orientation,
as determined by the generalized anomeric effect, matching the
conﬁgurational pattern of a-glucopyranosides.8 Accordingly, it
behaved as a potent and selective inhibitor of yeast a-glucosidase
(K i 2.2 mM), being inactive against several b-glucosidases.
Notwithstanding, a dramatic shift in the a/b-glucosidase selectiv-
itywas observed for cyclic isourea analogues bearing aliphatic sub-
stituents at the exocyclic nitrogen atom, e.g. 5 (K i 1.7 mM against
almond b-glucosidase; no inhibition of yeast a-glucosidase) even
though they likewise existed in the a-like conﬁguration in water
solution.9 Compound 5 was also a potent and selective inhibitor
of human lysosomal b-glucosidase (b-glucocerebrosidase, Glc-
Cerase). Most interestingly, it promoted the correct folding in
GlcCerase mutants associated with Gaucher disease and their
trafﬁcking to the lysosome, being currently under study as
pharmacological chaperone for the treatment of this pathology.10
X-Ray crystallographic studies showed that isourea 5 is actually
present in the b-conﬁguration in the active site of b-glucosidases.11
This enzyme-dependent inducedﬁt process is promotedby the sub-
stituent at the imine functionality, which locates in a hydrophobic
pocket at the vicinity of the active site of b-glucosidases resulting in
a remarkably high favourable entropic contribution to binding.11
Interestingly, replacement of the endocyclic oxygen atom by sulfur
or nitrogen increased the inhibitory potency for b-glucosidases
while preserving the anomeric selectivity (K i 0.76 and 0.42 mM
against almond b-glucosidase for isothiourea 6 and guanidine
7, respectively).12 Inversion of the conﬁguration at the position
equivalent to C-4 in monosaccharides, thereby shifting from a
hydroxylation pattern of structural complementarity to D-glucose
to a D-galactose-type proﬁle, further enhanced the inhibitory
potential against b-glucosidases (e.g.,K i 0.023 mMagainst almond
b-glucosidase for isothiourea 9 and K i 0.04 mM against bovine
liver b-glucosidase for guanidine 10). Actually, compounds 6–
10 also showed chaperone activity in Gaucher ﬁbroblasts with
several mutations, with isothiourea derivatives 6 and 9 being
the most active candidates followed by guanidine 7. Contrary
to classical sp3-iminosugars such as 1 or the corresponding N-
alkyl derivatives, the sp2-iminosugars were particularly active for
mutations leading to neuronopathic types of the disease.Mutation
proﬁling also evidenced differences in their chaperoning activity
that were mutation-dependent.10
Theabove commented results illustrate how structuralmodiﬁca-
tions in the skeleton and substitution proﬁle of sp2-iminosugar gly-
comimetics can be exploited to ﬁnely tune their enzyme inhibition
and pharmacological chaperone selectivity and potency even for
closely similar mutant enzymes. The implementation of synthetic
strategies allowing elaboration of a collection of derivatives for
structure–activity relationship (SAR) studies seemed therefore
very appealing. Given the promising results obtained with the
isothiourea and guanidine-type bicyclic cores both of the D-
gluco and D-galacto isosteric series in pharmacological chaperone
therapy approaches, a systematic investigation of the effect of a




In principle, the target bicyclic skeleton containing the isoth-
iourea or guanidine functionality I (X = S or NH) can be
obtained by intramolecular furanose→piperidine rearrangement
of 2-aminothiazoline or 2-aminoimidazoline pseudo-C-nucleoside
precursors (IIa), respectively, after liberating the aldehyde func-
tionality (IIb) of the monosaccharide. For iminothiazolidine
derivatives, the key thiazoline synthetic intermediate (II, X =
S) can be prepared from vicinal hydroxythiourea precursors III
following activationof theprimaryhydroxyl group for nucleophilic
displacement by the thiocarbonyl sulfur atom. This retrosynthetic
scheme is particularly appealing for generatingmolecular diversity
in an efﬁcient manner since thioureas can be readily prepared by
coupling of isothiocyanates and amines, which generally proceed
with total chemoselectivity and high yield in the presence of OH
functionalities.13 The corresponding imidazoline derivatives (II,
X = NH) could be obtained from 5,6-(cyclic isothiouronium) salt
intermediates IV by nucleophilic displacement of the alkylthio
group by amine (Fig. 2).12
Fig. 2 Retrosynthesis of bicyclic isothiourea and guanidine-type
sp2-iminosugars.






























































For practical reasons, the already reported 5-azido-5-deoxy-1,2-
O-isopropylidene-6-O-tetrahydropyranyl-a-D-glucofuranose and
5-azido-5-deoxy-1,2-O-isopropylidene-a-D-galactofuranose 1114
and 1215 were chosen as starting materials (Fig. 3). The cor-
responding 5-amino-5-deoxy-sugars can be readily generated
by catalytic hydrogenation and were used in the subsequent
coupling reactions without further puriﬁcation. For the synthesis
of thiourea intermediates III, we ﬁrst selected n-butyl isothio-
cyanate (13), 2,3,4,6-tetra-O-acetyl-b-D-glucopyranosyl isothio-
cyanate (14)16 and phenyl isothiocyanate (15) as representative
examples of alkyl, glycosyl and aryl substituted electrophile
counterparts, respectively. Since a preliminary screening revealed
the superiority of alkyl-bearing amphiphilic sp2-iminosugars as
b-glucosidase binders, a broader battery of alkyl isothiocyanate
building blocks was incorporated, including branched and lin-
ear derivatives bearing different chemical functionalities (16–21;
Fig. 3).
Fig. 3 Building block precursors for the synthesis of bicyclic isothiourea–
type sp2-iminosugars.
The selected isothiocyanate precursors were commercially
available (13, 15 and 18) or were obtained in a limited num-
ber of steps by isothiocyanation of the corresponding amines.
Thus, the glucopyranosyl derivative 14 was prepared from D-
glucose as reported in the literature.16 The branched isoth-
iocyanate 16 was synthesized from [bis(2-aminoethyl)-2-(tert-
butoxycarbonylamino)ethyl]amine (22)17 by N-hexanoylation of
the free primary amino groups (→23), subsequent deprotection of
the carbamate group (→24) and isothiocyanation of the generated
primary amine by treatment with thiophosgene. Compound 17
was obtained in good yield by isothiocyanation of the corre-
sponding amine 2518 using thiophosgene. The preparation of 4-
(1-adamantylcarboxamido)butyl isothiocyanate (19) was carried
out using a two-step process that involved condensation ofN-(tert-
butoxycarbonyl)butanediamine (26) and adamantane-1-carbonyl
chloride (→27) followed by carbamate hydrolysis and isothio-
cyanation. A similar strategy was followed for the preparation
of compound 20, incorporating an oligoethylene segment, from
11-azido-3,6,9-trioxaundecylamine (28)19 but in this case the
azido group in the amine adduct 29 was directly transformed
into isothiocyanate by reaction with triphenylphosphine–carbon
disulﬁde.20 Finally, the azidoalkyl isothiocyanate 21 was obtained
from 28 (Scheme 1) following isothiocyanationwith thiophosgene.
Scheme 1 Synthesis of the isothiocyanate precursors 16, 17, and 19–21.
The synthesis of the 5-N,6-S-(N¢-butyl-, N¢-b-D-glucopy-
ranosyl- and N¢-phenyl-iminomethylidene)-6-thionojirimycin
derivatives starts with reduction of the azido group in 11 by
catalytic hydrogenation, coupling of the resulting amine with
the corresponding isothiocyanate (13–15), acetylation and ﬁnal
hydrolysis of the tetrahydropyranyl group to afford the N¢-
thiourea adducts 30–32 (Scheme 2). Temporary protection of
the secondary hydroxyl as the corresponding acetate was consid-
ered advantageous in order to prevent regioselectivity problems






























































Scheme 2 Reagents and conditions: (a) 1. H2, Pd/C 10%, MeOH, r.t., 1 h. 2. 13–15, Et3N, pyridine, r.t., 18 h. 3. (1 : 1) Ac2O–pyridine, -15 ◦C, 5 h. 4.
p-TsOH, CH2Cl2–MeOH (1 : 1), r.t., 2 h; (b) MsCl, pyridine, -20 ◦C→ 10 ◦C, 7 h; (c) 1. NaOMe, MeOH, r.t., 30 min, solid CO2. 2. 90% TFA–H2O, r.t.,
30 min. 3. Amberlite IRA 68 (OH-); (d) 1. MsCl, pyridine, -20 ◦C→ 10 ◦C, 7 h. 2. NaOMe, MeOH, r.t., 30 min, solid CO2; (e) 1. 90% TFA–H2O, r.t.,
30 min. 2. Amberlite IRA 68 (OH-).
during the subsequent thiazoline ring formation. In the case
of the N¢-phenylthioureido derivative concomitant N-acetylation
occurred,21 leading to a 2 : 1 mixture of 32 and 33. This is not
detrimental for the overall yield of the reaction sequence as
discussed hereinafter. Attempts to activate the primary hydroxyl
as leaving group by triﬂuoromethanesulfonylation (triﬂation)22
in 30–33 were unsuccessful. Nevertheless, treatment with mesyl
chloride and pyridine at low temperature proceeded with spon-
taneous nucleophilic displacement of the transient mesylate by
the vicinal thiocarbonyl sulfur atom to afford the requested 2-
aminothiazolines with total selectivity in good yield (60–86%).
The thiourea sulfur is reported to react faster than the nitrogen
atoms in nucleophilic displacements, which is consistent with
the obtained result.23 In the case of the N¢-butyl and N¢-b-
D-glucopyranosyl derivatives the 3-O-acetyl derivatives 34 and
35 were thus characterized, whereas in the case of the of N¢-
phenylthioureas 32 and 33 the cyclization product was subjected
to subsequent deacetylation to yield the 2-aminothiazoline 36 as
the only reaction product (67%). Further removal of the protecting
groups afforded the target bicyclic nojirimycin derivatives 37–39
in 70–80% yield.
The synthesis of the 5-N,6-S-(N¢-iminomethylidene)-6-
thionojirimycin derivatives 52–57 followed a similar approach,
starting from azide 11 as a common intermediate. Protection of
the secondary hydroxyl group OH-3 in the thiourea derivatives
40–45 was found to be not necessary since the mesyl-promoted
cyclization proceeded with total regioselectivity to give the desired
thiazolines 46–51 (Scheme 3). This general synthetic strategy
was next applied to the preparation of the bicyclic galactono-
jirimycin derivatives 62 and 63, the C-4 epimers of compounds 37
and 39 (Scheme 4). 5-Azido-5-deoxy-1,2-O-isopropylidene-b-D-
galactofuranose (12), available from commercial a-D-galactose,15
was used as starting material for accessing the corresponding
thioureas 58 and 59, which were subjected to cyclization (→60
and 61) and ﬁnal pyranose→sp2-iminosugar rearrangement.
5-Deoxy-5-guanidinosugars can be accessed from the corre-
sponding 5-azido-5-deoxysugars via carbodiimide intermediates;24
however, their use as precursors of cyclic guanidines via nu-
cleophilic displacement of a vicinal sulfonate ester is not ap-
propriate due to the high basicity and low nucleophilicity of
the guanidine functionality. An alternative strategy was thus
developed for the preparation of 6-amino-6-deoxy-5,6-di-N¢-(N¢-
iminomethylidene)nojirimycin (70, 71) and galactonojirimycin
derivatives (72, 73) starting from the 5,6-(cyclic thiourea) interme-
diates 64 and 65.10,12 Transformation of the thioureas intoS-methyl
isothiouronium salts followed by reaction with n-butylamine or
benzylamine afforded the corresponding cyclic guanidines 66–69
in good yields, which were characterized as the corresponding
hydrochlorides. Deprotection of the acetal functionality and
treatment with sodium hydroxide gave the target sp2-iminosugar
glycomimetics 70–73, likewise characterized as the corresponding
hydrochloride salts (Scheme 5).
The structure and purity of all the prepared compounds were
conﬁrmed by spectroscopic and analytical techniques. The 13C
NMR spectra of the 2-aminothiazoline derivatives (34–36, 46–
51, 60, 61) showed a characteristic signal at 166.2–161.3 ppm
corresponding to the double bonded carbon and a high ﬁeld
shift of the C-6 resonance (37.9–33.3 ppm) with respect to the
thiourea precursors (30–33, 40–45, 58 and 59), conﬁrming the
replacement of oxygen by sulfur at this position. In the case
of the 2-aminoimidazoline derivatives (66–69) a signal at 159.9–
155.9 ppm conﬁrmed the presence of the imino functionality.






























































Scheme 3 Reagents and conditions: (a) 1. H2, Pd/C 10%, MeOH, r.t.,
1 h. 2. 16–21, Et3N, pyridine, r.t., 18 h. 3. p-TsOH, CH2Cl2–MeOH (1 : 1),
r.t., 2 h, 47–85%; (b) MsCl, pyridine, -20 ◦C→ 10 ◦C, 7 h, 46–78%; (c) 1.
90% TFA-H2O, r.t., 30 min. 2. Amberlite IRA 68 (OH-), 82–99%.
The 1H and 13C NMR spectra of the sp2-iminosugars (37–
39, 52–57, 62, 63, 70–73) registered in D2O solution conﬁrmed
their bicyclic character. Thus, the high ﬁeld resonance of the
pseudoanomeric carbon (C-1) resonance (76.7–74.9 ppm) was
in agreement with the presence of the hemiaminal functionality,
whereas the vicinal 3JH,H values about the six-membered ring were
indicative of the 4C1 chair conformation with the pseudoanomeric
groups in axial (a-like) orientation (J1,2 = 3.2–4.0 Hz) ﬁtting the
anomeric effect, a distinctive feature of sp2-iminosugars. In the
case of compounds with aliphatic substituents, the presence of the
b-like anomer in the solution was detected by NMR, but with a
large preference (>95%) for the a-like diastereomer.
Evaluation of the glycosidase inhibitory activity
All the new sp2-iminosugars synthesised were ﬁrst tested
as inhibitors against a series of commercial glycosidases
including a-glucosidase (yeast), b-glucosidase (almonds), b-
Scheme 4 Reagents and conditions: (a) 1. H2, Pd/C 10%,MeOH, r.t., 1 h.
2. 13 or 15, Et3N, pyridine, r.t., 18 h, 69–72%; (b) MsCl, pyridine, -20 ◦C
→ 10 ◦C, 7 h, 52–60%; (c) 1. 90% TFA–H2O, r.t., 30 min. 2. Amberlite
IRA 68 (OH-), 60–86%.
Scheme 5 Reagents and conditions: (a) 1.MeI,MeOH, 70 ◦C, 2 h, 90%. 2.
nBuNH2 or PhCH2NH2,DMF, 70
◦C, 18 h, 55–76%; (b) 1. 90%TFA–H2O,
0 ◦C, 1 h. 2. NaOH 0.1 N, 60–80%.
glucosidase (bovine liver, cytosolic), a-mannosidase (Jack bean),
b-mannosidase (Helix pomatia), trehalase (pig kidney), amy-
loglucosidase (Aspergillus niger), naringinase (b-glucosidase/a-
L-rhamnosidase; Penicillium decumbens),25 a-galactosidase (green
coffee beans), isomaltase (yeast), and a-L-fucosidase (pig kidney).
The corresponding inhibition constants (K i) are collected in
Tables 1 (for bicyclic nojirimycin derivatives) and 2 (for bicyclic
galactonojirimycin derivatives). The corresponding data for the
previously synthesized derivatives 5–10 have been also included
for comparative purposes.
In agreement with previous results on relatedN-substituted imi-
nomethylydene derivatives,9 no or weak inhibition of the glycosi-
dases acting on a-glucopyranosides, namely yeast a-glucosidase,
isomaltase or amyloglucosidase, was observed in all cases in spite
of the matching conﬁguration at the (pseudo)anomeric centre. It
must be noted, however, that except compounds 38 and 52 all
compounds with D-gluco conﬁgurational pattern were weak to
moderate inhibitors of pig kidney trehalase, an enzyme known
to be strongly inhibited by isourea and isothiourea derivatives
(Table 1).26 The isothiourea-type nojirimycin derivatives also






























































Table 1 K i values (mM) for the bicyclic nojirimycin derivatives 5–7, 37–39, 52–57, 70 and 71 against a panel of glycosidasesa
Enzyme 5 6 7 37 38 39 52 53 54 55 56 57 70 71
a-glucosidase (baker yeast) 168 n.i.b n.i. n.i. n.i. n.i. n.i. n.i. n.i. 292 n.i. n.i. n.i. n.i.
b-glucosidase (almond) 1.9 0.76 0.42 24 654 n.i 19 13 13 0.45 28 33 144 23
b-gluco/b-galactosidase (bovine liver) 2.7 3.7 35 58 251 383 24 9.3 256 68 165 126 508 85
trehalase (pig kidney) 182 13.4 40 20.1 n.i. 226 n.i. 24 116 103 433 398 87 154
naringinase (Penicillium decumbens) n.d.c 0.23 0.18 1.1 110 14 1.3 0.23 1.8 0.10 0.35 0.67 1.9 0.68
a-L-fucosidase (pig kidney) n.d. 18 260 6.2 48 2.4 151 2.6 10.8 7.1 17.6 4.4 514 529
Imiglucerase (Cerezyme R©, Genzyme)d 3.44 0.69 3.8 24.1 n.d. n.d. 5.9 n.d. n.d. 5.5 173 22.3 101 150
a Inhibition was competitive in all cases. No inhibition was observed for any compound at 2 mM concentration on green coffee bean a-galactosidase,
Aspergillus niger amyloglucosidase, Jack bean a-mannosidase or Helix pomatia b-mannosidase. b n.i., no inhibition observed at 2 mM concentration of
the inhibitor. c n.d., not determined. d IC50 values [mM].
inhibited pig kidney a-L-fucosidase in the low micromolar range
(Table 1).
Most interestingly, all the N¢-alkyl-substituted iminothiazoli-
dine derivatives (6, 37, 52–57) behaved as micromolar to nanomo-
lar inhibitors of the b-glucosidases from almonds and bovine liver
as well as of naringinase from Penicillium decumbens, an enzyme
having b-glucosidase (E.C. 3.2.1.21) and a-L-rhamnosidase (E.C.
3.2.1.40) activities, in spite of themismatching conﬁguration at the
pseudoanomeric centre. Compounds exhibiting strong inhibition
for the two ﬁrst b-glucosidases have been shown previously
to be good candidates as pharmacological chaperones for the
treatment of Gaucher disease. Therefore, this assay was used
to select compounds for further evaluation against human b-
glucocerebrosidase. The inhibition potency seems to be related
to the hydrophobicity of the N¢-substituent. Thus, incorporation
of a terminal protonatable amino group (i.e., 53 and 54) resulted
in a signiﬁcant increase in the corresponding K i values (2.5 and
4.4-fold in the case of the bovine liver enzyme) as compared
with the parent N¢-alkyl derivative (i.e., 6 and 37). Similarly,
compounds 56 and 57, incorporating a triethylene glycol moiety,
were one to two orders of magnitude weaker inhibitors than
compounds having hydrophobic substituents. This substantially
worse inhibition might have its origin in the high desolvation
energy of the polyethylene glycol-based arm, an effect that
increases with length.27
The mammalian b-glucosidase seems to be more sensitive to
modiﬁcations at the exocyclic nitrogen substituent of the inhibitor.
Thus, the adamantylcarboxamidobutyl derivative 55 was up to
1.7-fold a more potent inhibitor that the N¢-octyl derivative 6
against almond b-glucosidase but 18.4-fold weaker against bovine
liver b-glucosidase. Replacement of the octyl chain (i.e., in 7) into
butyl and phenyl (i.e., in 70 and 71, respectively) was also strongly
detrimental for the inhibitory activity in the cyclic guanidine-type
bicyclic nojirimycin series.
Comparison of the inhibition data for D-gluco (Table 1) and
D-galacto-conﬁgured compounds (Table 2) indicated that the later
tend to be more potent inhibitors against the b-glucosidases
from almonds and bovine liver (i.e., 7, 37, 39, and 70 versus 10,
62, 63, and 72, respectively). It is known that iminosugars with
hydroxylation patterns of stereochemical complementarity to D-
galactose are often moderate to good inhibitors of family 1 b-
glucosidases,28 which are not very selective enzymes regarding the
conﬁguration at C-4 in the substrates.
Compounds 5–10, 37, 52, 55–57, 62, 70, and 71were further eval-
uated as inhibitors of the recombinant GlcCerase (imiglucerase,
Cerezyme R© from Genzyme) (Tables 1 and 2). Activity data
reﬂect a clear dependence of GlcCerase inhibition on the nature
of the exocyclic substituent. In agreement with the correlation
between amphiphilicity and inhibitory activity observed in other
glycomimetic families,29 the inhibitory potency decreased when
decreasing the hydrophobicity of the N¢-substituent, irrespective
of the nature of the endocyclic heteroatom at the ﬁve-membered
ring. Thus, the presence of polar groups (e.g. 56 and 57 versus 55)
or shortening the aliphatic alkyl chain (i.e. 37, 62 and 70 versus
6, 9 and 7, respectively) involved a signiﬁcant diminution of the
inhibitory activity.
Evaluation of the potential for chaperoning activity
Enzyme stabilization under thermal denaturation conditions was
used as an indication of the potential of the target compounds to
behave as pharmacological chaperones.30 Recovery of GlcCerase
activity after heating at 48 ◦C was measured in the absence and
in the presence of increasing concentrations (50, 100 and 150 mM)
Table 2 K i values (mM) for 8, 9, 10, 62, 63, 72, and 73 against a panel of glycosidasesa
Enzyme 8 9 10 62 63 72 73
b-glucosidase (almond) 0.019 0.023 0.16 0.49 69 5.7 n.i.
a-galactosidase (green coffee bean) n.i.b n.i. n.i. 458 n.i. n.i. n.i.
b-gluco/b-galactosidase (bovine liver) 0.052 0.042 0.04 1.2 55 2.5 n.i.
naringinase (Penicillium decumbens) n.d.c 37 44 144 n.i. n.d. 63
a-L-fucosidase (pig kidney) n.d. 11 n.d. n.i. n.i. n.i. n.d.
Imiglucerase (Cerezyme R©, Genzyme)d 10.6 4.0 0.9 83 n.d. n.d. n.d.
a Inhibition was competitive in all cases. No inhibition was observed for any compound at 2 mM concentration on baker’s yeast a-glucosidase, pig
kidney trehalase, yeast isomaltase, Jack bean a-mannosidase or Helix pomatia b-mannosidase. b n.i., no inhibition observed at 2 mM concentration of
the inhibitor. c n.d., not determined. d IC50 values [mM].






























































Fig. 4 Relative enzymatic activity after thermal denaturation (48 ◦C) for 20 min, 40 min, and 60 min at the indicated inhibitor concentrations (mM)
compared to the corresponding assay at 37 ◦C. Data for control (C) are obtained as above except that no inhibitor is present.
of the selected sp2-iminosugars at different incubation times
(Fig. 4). Untreated GlcCerase lost most of its activity after
1 h of denaturation under these conditions (less than 10%
activity remained). Compounds 5, 6, 7, 9, 52, and 55 exhibited a
remarkable stabilization effect, whereas compounds 8, 37, 62, 10,
56, 57, 71 did not protect the enzyme against thermal inactivation.
Accordingly, this protective effect increased gradually with the
lipophilicity.
The stabilization activity of the sp2-iminosugars was challenged
against that of N-(n-nonyl)deoxynojirimycin (NNDNJ),29 an
amphiphilic iminosugar currently under investigation as pharma-
cological chaperone for Gaucher disease. Compound 5 behaved
similarly to NNDNJ, whereas compounds 6, 7, 9, 52, and 55
were signiﬁcantly more efﬁcient. For example, the recombinant
enzyme incubated with 50 mM 6 retained over 40% of the initial
activity after 1 h, which is eight-fold higher than the untreated
enzyme and about twice as comparedwith 50mMNNDNJ-treated
enzyme.32 The protective effect was strongly dose-dependent for
the D-gluco conﬁgured derivatives bearing the n-octyl substituent
(5–7), a feature also observed for NNDNJ, but was almost dose-
independent in the 50–150 mM range in the case of the branched
derivative 52, the adamantane derivative 55 and, especially, for the
bicyclic galactonojirimycin derivative 9. This might reﬂect that
those compounds have already reached the maximum stabilizing
activity at 50 mM, about 80% imiglucerase retained activity after
20 min at 48 ◦C. Although this compares unfavourably with 6 or
7 (about 100 and 90% retained activity at 150 mM M after 20 min,
respectively), it should be noted that 9, 52 and 55 are much more
efﬁcient at protecting the enzyme over longer period of times (e.g.,
60% activity after 60 min in the presence of 50 mM of 9 or 70%
after 60 min in the presence of 150 mM of 52; to be compared
with only 50% for 6 or NNDNJ after 60 min at 150 mM),30
whichmakes them very attractive candidates for further biological
studies.
It is worth noting that the ensemble of results above dis-
cussed evidences that the inhibitory activity is not necessarily
correlated with the enzyme stabilization effect. Thus, compounds
5–7 and 8–10 very similarly inhibited imiglucerase (Tables 1
and 2) but behaved quite differently in the thermal-denaturation
protection assay, with compounds 8 and 10 being actually
inactive.
Conclusions
In summary, a general strategy for the preparation of bicyclic
nojirimycin and galactonojirimycin related sp2-iminosugars ana-
logues adapted to molecular diversity-oriented schemes has been
disclosed and applied to the synthesis of a library of glycomimet-
ics differing in C-4 conﬁguration (D-gluco and D-galacto), the
structure of the ﬁve-membered ring (cyclic isourea, isothiourea
or guanidine) and the nature of the N¢-substituent (apolar,
polar, linear or branched). Glycosyl hydrolase inhibition studies
evidenced a remarkable inﬂuence of the nature of the exocyclic
substituent on the potency and selectivity of binding towards a
range of commercial glycosidases, although selectivity towards
b-glucosidases was generally observed. Amphiphilic derivatives
bearing hydrophobicN¢-substituents weremuchmore potent than
derivatives bearing polar substituents, which also correlated with
potent inhibition of the recombinant human b-glucocerebrosidase
(imiglucerase) used in enzyme replacement therapy for Gaucher
disease. We have further tested the ability of these compounds
to increase imiglucerase stability against thermal denaturation,
as an in vitro assessment of their potential as pharmacological
chaperones. Analysis of the results in comparison with data for the
iminosugar derivative NNDNJ evidenced the higher chaperoning
potency of sp2-iminosugars and stresses their potential in phar-
macological chaperone therapy and combined therapy strategies.
Experimental
General methods
Reagents and solvents were purchased from commercial sources
and used without further puriﬁcation. Optical rotations were
measured with a JASCO P-2000 polarimeter, using a sodium
lamp (l = 589 nm) at 22 ◦C in 1 cm or 1 dm tubes. IR
spectra were recorded on a JASCO FTIR-410 instrument. UV
spectra were recorded on Philips PU-8710 instrument, unit for
e values: mm-1cm-1. NMR experiments were performed at 300
(75.5), 400 (100.6), and 500 (125.7) MHz using Bruker DMX300,
DRX400, and DRX500. 1-D TOCSY as well as 2-D COSY
and HMQC experiments were carried out to assist in signal
assignment. In the FABMS spectra, the primary beam consisted






























































of Xe atoms with maximum energy of 8 keV. The samples were
dissolved in m-nitrobenzyl alcohol or thioglycerol as the matrices
and the positive ions were separated and accelerated over a
potential of 7 keV. NaI was added as cationizing agent. Thin-
layer chromatography was performed on E. Merck precoated
TLC plates, silica gel 30F-245, with visualization by UV light
and by charring with 10% H2SO4 or 0.2% w/v cerium(IV) sulfate-
5% ammonium molybdate in 2 M H2SO4 or 0.1% ninhydrin in
EtOH. Column chromatography was performed on Chromagel
(SDS silica 60 AC.C, 70–200 mm). Elemental analyses were
performed at the Servicio de Microana´lisis del Instituto de In-
vestigaciones Quı´micas de Sevilla, Spain. 5-Azido-5-deoxy-1,2-O-
isopropylidene-6-O-tetrahydropyranyl-a-D-glucofuranose 11 was
prepared from commercial 6,3-D-glucuronolactone following
the procedure already reported.14 2,3,4,6-Tetra-O-acetyl-b-D-
glucopyranosyl isothiocyanate (14) was synthesized from the
corresponding per O-acetyl glucopyranosyl bromide following
the procedure of Camarasa et al.16 5-Azido-5-deoxy-1,2-di-O-
isopropylidene-a-D-galactofuranose 12 was obtained from D-
galactose using the reported route.15 The cyclic thiourea a-D-
glucofuranose derivative 64 was prepared from commercial 6,3-
D-glucuronolactone following the procedure already reported.12
The cyclic thiourea a-D-galactofuranose derivative 65 was syn-
thesized from 5-azido-3-O-benzoyl-5-deoxy-a-D-galactofuranose
following the reported route.10
General procedure for the inhibition assay against the commercial
enzymes
Inhibition constant (K i) values were determined by spectropho-
tometrically measuring the residual hydrolytic activities of the
glycosidases against the respective o- (for b-glucosidase from
bovine liver) or p-nitrophenyla- or b-D-glycopyranoside (for other
glycosidases) or a,a¢-trehalose (for trehalase) in the presence of
compounds 37–39, 52–57, 62, 63, and 70–73. Each assay was
performed in phosphate buffer or phosphate-citrate buffer (for
a- or b-mannosidase and amyloglucosidase) at the optimal pH
for the enzymes. The reactions were initiated by addition of
enzyme to a solution of the substrate in the absence or presence of
various concentrations of inhibitor. The mixture was incubated
for 10–30 min at 37 ◦C or 55 ◦C (for amyloglucosidase) and
the reaction was quenched by addition of 1 M Na2CO3 or a
solution of GLC-Trinder (Sigma, for trehalase). Reaction times
were appropriate to obtain 10–20% conversion of the substrate
in order to achieve linear rates. The absorbance of the resulting
mixture was determined at 405 nm or 505 nm (for trehalase).
Approximate values of K i were determined using a ﬁxed con-
centration of substrate (around the KM value for the different
glycosidases) and various concentrations of inhibitor. Full K i
determinations and enzyme inhibition mode were determined
from the slope of Lineweaver–Burk plots and double reciprocal
analysis. Representative examples of the Lineweaver–Burk plots,
with typical proﬁle for competitive inhibition mode, are shown in
the Electronic Supplementary Information.†
Imiglucerase inhibition assay
In vitro activity was determined with 4 mM 4-methylumbelliferyl-
b-D-glucopyranoside in McIlvaine buffer (pH 5.2). Enzyme so-
lutions (25 mL from a stock solution containing 0.1 mg of
protein/mL) in the presence of 0.2% (w/v) sodium taurocholate
and 0.1% (v/v) TritonX-100 in McIlvaine buffer (pH 5.2)
were incubated at 37 ◦C without (control) or with inhibitor
during 30 min, and after addition of corresponding substrate
solution (60 mL), incubations were maintained at 37 ◦C for
10 min. Enzymatic reactions were stopped by the addition of
150 mL of 100 mm glycine/NaOH buffer (pH 10.6). The amount
of 4-methylumbelliferone formed was determined with a 1420
VICTOR2 Multilabel Counter (Wallac) ﬂuorometer at 355 nm
(excitation) and 460 nm (emission). IC50 values were determined
byplotting percent activity versus log [I ], using at least ﬁve different
inhibitor concentrations.
Thermal stabilization assay
Following a modiﬁcation of a reported method,31 Imiglucerase
aliquots (48 mL, 2 mg ml-1) were incubated at pH 7.4 with 0
(control), 150, 100, or 150 mm test compound at 48 ◦C. Subse-
quently, 150 mL of 0.1 m acetate–phosphate buffer (pH 5.0) and
100 mL of substrate (4 mM 4-methyllumbelliferyl b-D-glucoside)
in McIlvaine buffer (pH 5.2) were added at different times and
incubated for 10 min at 37 ◦C, in the presence of 0.l% Triton X-
100 and 0.2% taurodeoxycholic acid. Then an amount of 300 mL
of glycine/NaOH buffer (100 mM, pH 10.6) was added and
liberated 4-methylumbelliferone was measured. Enzyme activity
was reported relative to that of the enzyme at 37 ◦C.
General procedure for the synthesis of 5-thioureido-a-D-
glucofuranose derivatives 30–33 and 40–45. A solution of
5-azido-5-desoxy-1,2-O-isopropylidene-6-O-tetrahydropyranyl-
a-D-glucofuranose14 11 (300 mg, 0.91 mmol) in MeOH (5 mL)
was hydrogenated at atmospheric pressure for 1 h using 10%
Pd/C (90 mg) as catalyst. The suspension was ﬁltered through
Celite and concentrated. To a solution of the resulting residue
in pyridine (6 mL), Et3N (0.71 mL, 5.1 mmol, 5.6 eq) and the
corresponding isothiocyanate (1.1 mmol, 1.2 eq) were added and
the mixture was stirred at room temperature for 18 h. In the case
of 30–33 the reaction mixture was cooled at -15 ◦C, Ac2O (3 mL)
was added dropwise, and the mixture was further stirred for 5 h.
Then, the solvent was removed under reduced pressure and the
resulting residue coevaporated several times with toluene. The
crude product was dissolved in CH2Cl2–MeOH (1 : 1, 12 mL) and
p-toluenesulfonic acid (50 mg, 0.26 mmol, 0.3 eq) was added. The
reaction mixture was stirred for 2 h at room temperature, and
then diluted with CH2Cl2 (8 mL), washed with saturated aqueous
NaHCO3 (2 ¥ 8 mL), dried (MgSO4), and concentrated. The
resulting residue was puriﬁed by column chromatography using
the eluent indicated in each case.
3-O-Acetyl-5-(N ¢-butylthioureido)-5-deoxy-1,2-O-isopropyli-
dene-a-D-glucofuranose (30). Column chromatography, eluent
50 : 1 CH2Cl2–MeOH. Yield: 220 mg (64%). [a]D -24.7 (c 1.0,
CH2Cl2). Rf 0.32 (20 : 1 CH2Cl2–MeOH). IR (KBr) nmax 2929,
1747, 1375, 1070 cm-1. UV (CH2Cl2) 251 nm (emM 15.1). 1H NMR
(500 MHz, CDCl3, 323 K) d 6.26 (bs, 1 H, N¢H), 6.16 (bd, 1 H,
J5,NH = 7.9 Hz, NH), 5.88 (d, 1 H, J1,2 = 3.7 Hz, H-1), 5.28 (d,
1 H, J3,4 = 3.1 Hz, H-3), 4.79 (m, 1 H, H-5), 4.46 (d, 1 H, H-2),
4.44 (dd, 1 H, J4,5 = 7.9 Hz, H-4), 3.91 (dd, 1 H, J6a,6b = 11.3 Hz,
J5,6a = 3.5 Hz, H-6a), 3.82 (dd, 1 H, J5,6b = 3.3 Hz, H-6b), 3.33 (m,






























































2 H, CH2N), 2.11 (s, 3 H, MeCO), 1.54 (m, 2 H, CH2CH2N), 1.48,
1.28 (2 s, 6 H, CMe2), 1.36 (m, 2 H, CH2CH3), 0.92 (t, 3 H, 3JH,H =
7.4 Hz, CH3). 13CNMR (125.7MHz, CDCl3, 313K) d 182.1 (CS),
169.9 (CO), 112.3 (CMe2), 104.8 (C-1), 83.4 (C-2), 78.4 (C-4), 75.7
(C-3), 62.7 (C-6), 53.8 (C-5), 43.9 (CH2N), 30.9 (CH2CH2N), 26.6,
26.1 (CMe2), 21.3 (MeCO), 20.0 (CH2CH3), 13.6 (CH3). ESIMS:
m/z 375 [M - H]+. Anal. Calcd for C16H28N2O6S: C, 51.05; H,
7.50; N, 7.44. Found: C, 50.88; H, 7.36; N, 7.33%.
3-O-Acetyl-5-deoxy-1,2-O-isopropylidene-5-[N ¢-(2,3,4,6-tetra-
O-acetyl-b-D-glycopyranosyl)thioureido]-a-D-glucofuranose (31).
Column chromatography, eluent 1 : 1 → 2 : 1 EtOAc–petroleum
ether. Yield: 456 mg (77%). [a]D -6.9 (c 1.0, CH2Cl2). Rf 0.46
(2 : 1 EtOAc-petroleum ether). UV (CH2Cl2) 255 nm (emM 12.6).
IR (KBr) nmax 2942, 1749, 1375, 1038 cm-1. 1H NMR (300 MHz,
CDCl3, 313 K) d 6.84 (d, 1 H, JNH,5 = 8.7 Hz, NH), 6.76 (bd, 1 H,
N¢H), 5.93 (d, 1 H, J1,2 = 3.7 Hz, H-1), 5.55 (t, 1 H, J1¢,2¢ = J1¢,N¢H =
9.4 Hz, H-1¢), 5.34 (t, 1 H, J2¢,3¢ = J3¢,4¢ = 9.4 Hz, H-3¢), 5.29 (d,
1 H, J3,4 = 3.0 Hz, H-3), 5.07 (t, 1 H, J4¢,5¢ = 9.4 Hz, H-4¢), 5.00
(t, 1 H, H-2¢), 4.78 (m, 1 H, H-5), 4.50 (d, 1 H, H-2), 4.46 (dd,
1 H, J4,5 = 7.8 Hz, H-4), 4.27 (dd, 1 H, J6¢a,6¢b = 12.4 Hz, J5¢,6¢a =
4.7 Hz, H-6¢a), 4.15 (dd, 1 H, J5¢,6¢b = 5.2 Hz, H-6¢b), 3.98 (dd, 1 H,
J6a,6b = 11.4 Hz, J5,6a = 2.9 Hz, H-6a), 3.85 (dd, 1 H, J5,6b = 2.9 Hz,
H-6b), 3.84 (m, 1 H, H-5¢), 2.15, 2.09, 2.08, 2.04, 2.03 (s, 15 H,
MeCO), 1.51, 1.32 (2 s, 6 H, CMe2). 13CNMR (75.5MHz, CDCl3,
313 K) d 184.0 (CS), 171.4, 170.7, 169.9, 169.8, 169.5 (MeCO),
112.3 (CMe2), 104.7 (C-1), 83.4 (C-2), 82.6 (C-1¢), 77.9 (C-4), 75.7
(C-3), 73.3 (C-3¢), 73.0 (C-5¢), 71.0 (C-2¢), 68.5 (C-4¢), 62.1 (C-6),
61.9 (C-6¢), 53.8 (C-5), 26.6, 26.0 (CMe2), 21.2, 20.7, 20.6, 20.5
(MeCO). FABMS: m/z 674 (100, [M + Na]+), 652 (15, [M + H]+).
Anal. Calcd for C26H38N2O15S: C, 47.99; H, 5.89; N, 4.31. Found:
C, 47.84; H, 5.66; N, 4.24%.
3-O-Acetyl-5-deoxy-1,2-O-isopropylidene-5-(N ¢-phenylthio-
ureido)-a-D-glucofuranose (32). Column chromatography, eluent
100 : 1→ 30 : 1 CH2Cl2–MeOH.Yield: 202mg (56%). [a]D -51.0 (c
1.0,CH2Cl2).Rf 0.27 (20 : 1CH2Cl2–MeOH).UV (CH2Cl2) 268nm
(emM 13.3). IR (KBr) nmax 3052, 1741, 1524, 1370, 1076 cm-1. 1H
NMR (500 MHz, CDCl3, 313 K) d 7.97 (bs, 1 H, N¢H), 7.42–7.22
(m, 5 H, Ph), 6.54 (d, 1 H, J5,NH = 9.0 Hz, NH), 5.88 (d, 1 H, J1,2 =
3.7 Hz, H-1), 5.25 (d, 1 H, J3,4 = 3.0 Hz, H-3), 4.94 (m, 1 H, H-5),
4.45 (d, 1 H, H-2), 4.38 (dd, 1 H, J4,5 = 7.8 Hz, H-4), 3.90 (dd, 1 H,
J6a,6b = 11.3 Hz, J5,6a = 3.1 Hz, H-6a), 3.80 (dd, 1 H, J5,6b = 3.4 Hz,
H-6b), 2.02 (s, 3 H, MeCO), 1.46, 1.27 (2 s, 6 H, CMe2). 13C NMR
(125.7MHz, CDCl3, 313K) d 180.7 (CS), 169.8 (CO), 136.0–125.2
(Ph), 112.4 (CMe2), 104.6 (C-1), 83.3 (C-2), 78.0 (C-4), 75.7 (C-3),
62.3 (C-6), 54.5 (C-5), 26.7, 26.1 (CMe2), 21.3 (MeCO). FABMS:
m/z 419 (75, [M + Na]+), 397 (100, [M + H]+). Anal. Calcd for
C18H24N2O6S: C, 54.53; H, 6.10; N, 7.07. Found: C, 54.36; H, 5.99;
N, 6.88%.
3-O-Acetyl-5-(N ¢-acetyl-N ¢-phenylthioureido)-5-deoxy-1,2-O-
isopropylidene-a-D-glucofuranose (33). Column chromatogra-
phy, eluent 100 : 1→ 30 : 1 CH2Cl2–MeOH. Yield: 136 mg (34%).
[a]D +37.4 (c 1.1, CH2Cl2). Rf 0.53 (20 : 1 CH2Cl2–MeOH). UV
(CH2Cl2) 277 nm (emM 9.1), 230 nm (emM 10.3). IR (KBr) nmax 3479,
3090, 2935, 1747, 1677, 1523, 1370, 1217, 1070 cm-1. 1H NMR
(500 MHz, CDCl3, 313 K) d 7.46–7.20 (m, 5 H, Ph), 5.93 (d, 1 H,
J1,2 = 3.7 Hz, H-1), 5.42 (d, 1 H, J3,4 = 2.9 Hz, H-3), 4.96 (m, 1 H,
H-5), 4.57 (dd, 1 H, J4,5 = 9.1 Hz, H-4), 4.49 (d, 1 H, H-2), 3.96 (m,
2 H, H-6a, H-6b), 2.07 (s, 3 H, MeCO), 1.92 (s, 3 H, MeCONH),
1.53, 1.30 (2 s, 6 H, CMe2). 13C NMR (125.7 MHz, CDCl3, 313
K) d 184.6 (CS), 175.1 (CO amide), 169.8 (CO ester), 142.3–128.9
(Ph), 112.5 (CMe2), 105.0 (C-1), 83.5 (C-2), 77.9 (C-4), 75.3 (C-
3), 62.1 (C-6), 55.5 (C-5), 28.0 (MeCONH), 26.8, 26.2 (CMe2),
21.6 (MeCO). FABMS: m/z 461 (15, [M + Na]+), 439 (30, [M +
H]+). FABMSHR m/z 461.136042. Calcd for C20H26N2O7NaS:
461.135843.
5-[N ¢-(N ,N -Bis(2-hexanamidoethyl)aminoethyl)thioureido]-5-
deoxy-1,2-O-isopropylidene-a-D-glucofuranose (40). Column
chromatography, eluent 40 : 1 → 20 : 1 CH2Cl2–MeOH. Yield:
204 mg (47%). [a]D +35.4 (c 1.0, CH2Cl2). Rf 0.49 (10 : 1 CH2Cl2–
MeOH). IR (KBr) nmax 3296, 2956, 1646, 1374, 1074 cm-1. UV
(CH2Cl2) 241 nm (emM 16.0). 1H NMR (300 MHz, CDCl3, 313
K) d 7.82 (bs, 1 H, N¢H), 7.35 (d, 1 H, J5,NH = 8.7 Hz, NH),
6.22 (bs, 2 H, NHCO), 5.92 (d, 1 H, J1,2 = 3.6 Hz, H-1), 5.17
(bs, 1 H, OH), 4.63 (m, 1 H, H-5), 4.55 (d, 1 H, H-2), 4.17 (d,
1 H, J3,4 = 1.8 Hz, H-3), 4.10 (dd, 1 H, J4,5 = 10.1 Hz, H-4),
3.99 (dd, 1 H, J6a,6b = 11.3 Hz, J5,6a = 3.4 Hz, H-6a), 3.80 (dd, 1
H, J5,6b = 3.2 Hz, H-6b), 3.49 (m, 2 H, CH2NH), 3.49 (m, 4 H,
CH2NHCO), 2.66 (t, 2 H, 3JH,H = 5.1 Hz, CH2CH2NH), 2.55 (t,
4 H, 3JH,H = 5.3 Hz, CH2CONH), 2.18 (t, 4 H, 3JH,H = 7.3 Hz,
CH2CH2NHCO), 1.61 (m, 4 H, CH2CH2CONH), 1.48, 1.31 (2 s,
6 H, CMe2), 1.29 (m, 8 H, CH2), 0.88 (t, 6 H, 3JH,H = 6.7 Hz, CH3).
13C NMR (75.5 MHz, CDCl3) d 182.5 (CS), 174.5 (CO), 111.5
(CMe2), 105.1 (C-1), 84.6 (C-2), 80.5 (C-4), 73.9 (C-3), 63.0 (C-6),
54.9 (CH2CH2NHCO), 53.6 (C-5), 53.4 (CH2CH2NH), 42.7
(CH2NH), 38.0 (CH2NHCO), 36.7 (CH2CONH), 31.4 (CH2),
26.8, 26.1 (CMe2), 25.3 (CH2CH2CONH), 22.3 (CH2CH3), 13.8
(CH3). FABMS: m/z 626 (50, [M + Na]+), 604 (35, [M + H]+).
Anal. Calcd for C28H53N5O7S: C, 55.70; H, 8.85; N, 11.60. Found:
C, 55.75; H, 8.68; N, 11.52%.
5-[N ¢-(8-tert-Butoxycarbonylaminooctyl)thioureido]-5-deoxy-
1,2-O-isopropylidene-a-D-glucofuranose (41). Column chroma-
tography, eluent 40 : 1 → 30 : 1 CH2Cl2–MeOH. Yield: 219 mg
(67%). [a]D +42.6 (c 1.0, CH2Cl2). Rf 0.20 (20 : 1 CH2Cl2–MeOH).
IR (KBr) nmax 3336, 2977, 1683, 1368, 1074 cm-1. UV (CH2Cl2)
246 nm (emM 14.1). 1H NMR (400 MHz, CDCl3, 313 K) d 6.58 (bs,
2 H, NH), 5.93 (d, 1 H, J1,2 = 3.6 Hz, H-1), 5.07 (bs, 1 H, OH),
4.65 (m, 1 H, H-5), 4.59 (d, 1 H, H-2), 4.20 (s, 1 H, H-3), 4.11
(m, 1 H, H-4, H-6a), 3.78 (dd, 1 H, J6a,6b = 10.5 Hz, J5,6b = 1.7 Hz,
H-6b), 3.45 (m, 2H, CH2NHCS), 3.20 (bs, 1H,NH), 3.10 (m, 2H,
CH2NHCO), 2.07 (bs, 1 H, OH), 1.60 (m, 2 H, CH2CH2NHCS),
1.51, 1.33 (2 s, 6 H, CMe2), 1.48 (m, 2H, CH2CH2NHCO), 1.46 (s,
9 H, CMe3), 1.33 (m, 8 H, CH2). 13C NMR (100.6 MHz, CDCl3,
313 K) d 181.4 (CS), 156.5 (CO), 111.6 (CMe2), 104.9 (C-1), 84.6
(C-2), 79.7 (C-4), 79.2 (CMe3), 73.8 (C-3), 62.3 (C-6), 53.7 (C-
5), 44.3 (CH2NHCS), 40.6 (CH2NHCO), 29.8, 28.8, 28.7, 28.6
(CH2), 28.4 (CMe3), 26.7, 26.0 (CMe2), 26.5, 26.4 (CH2). FABMS:
m/z 528 (100, [M + Na]+), 506 (35, [M + H]+). Anal. Calcd for
C23H43N3O7S: C, 54.63; H, 8.57; N, 8.31. Found: C, 54.44; H, 8.42;
N, 8.24%.
5-[N ¢-(4-tert-Butoxycarbonylaminobutyl)thioureido]-5-deoxy-
1,2-O-isopropylidene-a-D-glucofuranose (42). Column chroma-
tography, eluent 30 : 1 → 15 : 1 CH2Cl2–MeOH. Yield: 204 mg
(70%). [a]D +45.5 (c 1.0, CH2Cl2). Rf 0.33 (15 : 1 CH2Cl2–MeOH).
IR (KBr) nmax 2933, 1682, 1367, 1075 cm-1. UV (CH2Cl2) 247 nm






























































(emM 12.3). 1H NMR (300 MHz, CDCl3, 313 K) d 6.96 (bs, 1 H,
N¢H), 6.96 (bd, 1H, JNH,5 = 7.8Hz, NH), 5.92 (d, 1H, J1,2 = 3.6Hz,
H-1), 5.07 (bs, 1 H, OH), 4.82 (bs, 1 H, NH), 4.58 (d, 1 H, H-2),
4.54 (m, 1 H, H-5), 4.19 (d, 1 H, J3,4 = 1.9 Hz, H-3), 4.09 (dd, 1 H,
J4,5 = 9.8 Hz, H-4), 4.03 (dd, 1 H, J6a,6b = 11.3 Hz, J5,6a = 3.1 Hz, H-
6a), 3.80 (dd, 1 H, J5,6b = 3.0 Hz, H-6b), 3.47 (m, 2 H, CH2NHCS),
3.11 (m, 2 H, CH2NHCO), 1.60 (m, 4 H, CH2), 1.49, 1.31 (2 s, 6 H,
CMe2), 1.49 (s, 9 H, CMe3). 13C NMR (75.5 MHz, CDCl3, 313 K)
d 181.8 (CS), 156.7 (CO), 111.6 (CMe2), 104.9 (C-1), 84.7 (C-2),
79.8 (CMe3), 79.7 (C-4), 73.8 (C-3), 62.4 (C-6), 53.7 (C-5), 44.1
(CH2NHCS), 40.2 (CH2NHCO), 28.4 (CMe3), 27.4 (CH2), 26.7,
26.0 (CMe2), 25.7 (CH2). FABMS: m/z 472 (100, [M + Na]+), 450
(15, [M + H]+). Anal. Calcd for C19H35N3O7S: C, 50.76; H, 7.85;
N, 9.35, S, 7.13. Found: C, 50.78; H, 7.93; N, 9.28; S, 6.96%.
5 - [N ¢ - (4 -Adamantan - 1 - ylcarbonylaminobutyl)thioureido] - 5 -
deoxy-1,2-O-isopropylidene-a-D-glucofuranose (43). Column
chromatography, eluent 1 : 1 acetone–cyclohexane. Yield: 236 mg
(71%). [a]D +29.5 (c 1.0, CH2Cl2). Rf 0.44 (1 : 1 acetone-
cyclohexane). IR (KBr) nmax 2909, 1627, 1374, 1074 cm-1. UV
(CH2Cl2) 246 nm (emM 9.8). 1H NMR (300 MHz, CDCl3, 313 K)
d 6.75 (bd, 1 H, 3JNH,H-5 = 8.6 Hz, NH), 5.92 (d, 1 H, J1,2 = 3.6 Hz,
H-1), 5.91 (bs, 1 H, N¢H), 5.29 (bs, 1 H, OH), 4.60 (d, 1 H, H-2),
4.52 (m, 1 H, H-5), 4.18 (s, 1 H, H-3), 4.12 (d, 1 H, J4,5 = 10.0 Hz,
H-4), 4.02 (dd, 1 H, J6a,6b = 11.2 Hz, J5,6a = 3.3 Hz, H-6a), 3.83 (dd,
1 H, J5,6b = 3.1 Hz, H-6b), 3.48 (m, 2 H, CH2NHCS), 3.26 (m, 2
H, CH2NHCO), 2.05 (bs, 3 H, CH), 1.83 (m, 6 H, CCH2) 1.73 (m,
6 H, CHCH2), 1.62 (m, 4 H, CH2), 1.49, 1.26 (2 s, 6 H, CMe2).
13C NMR (75.5 MHz, CDCl3, 313 K) d 182.1 (CO), 179.3 (CO),
111.6 (CMe2), 105.0 (C-1), 84.7 (C-2), 79.8 (C-4), 73.8 (C-3),
62.6 (C-6), 53.7 (C-5), 44.0 (CH2NHCS), 40.7 (CCONH), 39.3
(CH), 38.8 (CH2NHCO), 36.4 (CCH2), 28.1 (CHCH2), 27.3, 26.8
(CH2), 26.1, 25.3 (CMe2). FABMS: m/z 534 (100, [M + Na]+),
512 (25, [M + H]+). Anal. Calcd for C25H41N3O6S: C, 58.68; H,
8.08; N, 8.21; S, 6.27. Found: C, 58.84; H, 7.91; N, 8.12, S, 5.94%.
5-[N ¢-(11-Azido-3,6,9-trioxaundecyl)thioureido]-5-deoxy-1,2-O-
isopropylidene-a-D-glucofuranose (44). Column chromatogra-
phy, eluent 40 : 1→ 30 : 1 CH2Cl2–MeOH. Yield: 150 mg (48%).
[a]D +43.7 (c 1.0, CH2Cl2). Rf 0.49 (10 : 1 CH2Cl2–MeOH). IR
(KBr) nmax 2932, 2108, 1375, 1075 cm-1. UV (CH2Cl2) 246 nm (emM
14.4). 1H NMR (500 MHz, CDCl3, 313 K) d 6.90 (bs, 2 H, NH),
5.94 (d, 1H, J1,2 = 3.6Hz, H-1), 4.97 (bs, 1H, OH), 4.58 (d, 1H,H-
2), 4.56 (m, 1H,H-5), 4.20 (s, 1H,H-3), 4.10 (d, 1H, J4,5 = 10.0Hz,
H-4), 4.06 (bd, 1 H, J6a,6b = 10.1 Hz, H-6a), 3.82(dd, 1 H, J5,6b =
2.4 Hz, H-6b), 3.79 (m, 2 H, CH2NH), 3.69 (m, 12 H, OCH2), 3.44
(t, 1 H, 3JH,H = 5.2 Hz, CH2N3), 2.94 (bs, 1 H, NH), 2.94 (bs, 1 H,
OH), 1.51, 1.33 (2 s, 6 H, CMe2). 13C NMR (125.7 MHz, CDCl3,
313 K) d 182.4 (CS), 111.6 (CMe2), 105.0 (C-1), 84.7 (C-2), 79.8
(C-4), 73.7 (C-3), 71.4, 70.6, 70.5, 70.2, 69.9 (OCH2), 62.4 (C-6),
53.7 (C-5), 50.8 (CH2N3), 44.9 (CH2NH), 42.6 (CH2CH2N3), 26.7,
26.1 (CMe2). FABMS: m/z 502 (100, [M + Na]+), 480 (45, [M +
H]+). Anal. Calcd for C18H33N5O8S: C, 45.08; H, 6.94; N, 14.60.
Found: C, 44.85; H, 6.76; N, 14.46%.
5-[N ¢-(11-Adamantan-1-ylcarbonylamino-3,6,9-trioxaundecyl)-
thioureido] - 5 - deoxy - 1,2 -O - isopropylidene -a - D - glucofuranose
(45). Column chromatography, eluent 1 : 2 → 1 : 1 acetone–
cyclohexane. Yield: 340 mg (85%). [a]D +30.4 (c 1.0, CH2Cl2). Rf
0.36 (1 : 1 acetone-cyclohexane). IR (KBr) nmax 2906, 1634, 1350,
1076 cm-1. UV (CH2Cl2) 243 nm (emM 16.3). 1H NMR (300 MHz,
CDCl3, 313 K) d 7.25 (bs, 2 H, NH), 6.17 (bs, 1 H, NH), 5.93 (d,
1 H, J1,2 = 3.6 Hz, H-1), 4.63 (m, 1 H, H-5), 4.57 (d, 1 H, H-2),
4.19 (d, 1 H, J3,4 = 1.7 Hz, H-3), 4.10 (dd, 1 H, J4,5 = 10.0 Hz,
H-4), 4.02 (dd, 1 H, J6a,6b = 11.3 Hz, J5,6a = 3.2 Hz, H-6a), 3.82
(dd, 1 H, J5,6b = 3.2 Hz, H-6b), 3.64 (m, 14 H, OCH2, CH2NHCS),
3.45 (m, 2 H, CH2NHCO), 2.06 (bs, 3 H, CH), 1.86 (m, 6 H,
CCH2), 1.74 (m, 6 H, CH2), 1.49, 1.32 (2 s, 6 H, CMe2). 13C
NMR (75.5 MHz, CDCl3, 313 K) d 182.5 (CS), 178.8 (CO), 111.5
(CMe2), 105.0 (C-1), 84.7 (C-2), 80.0 (C-4), 73.8 (C-3), 70.7, 70.5,
70.3, 70.1, 69.9 (OCH2), 62.5 (C-6), 53.7 (C-5), 44.9 (CH2NHCS),
40.7 (CCONH), 39.3 (CH2NHCO), 39.2 (CH), 36.5 (CCH2), 28.1
(CH2), 26.8, 26.1 (CMe2). FABMS: m/z 638 (100, [M + Na]+).
Anal. Calcd for C29H49N3O9S: C, 56.56; H, 8.02; N, 6.82. Found:
C, 56.45; H, 7.90; N, 6.72%.
General procedure for the synthesis of (4R)-4-(L-treofuranos-
4¢-yl)-2-amino-2-thiazoline derivatives 34–36 and 46–51. To a
solution of the corresponding thioureido derivative 30–33 and
40–45 (0.86 mmol) in pyridine (23 mL) at -20 ◦C under Ar,
methanesulfonic chloride (80 mL, 1.03 mmol, 1.2 eq) was added.
The reaction mixture was stirred for 7 h and allowed to warm
to 10 ◦C. Then, ice-water (30 mL) was added and the solution
was extracted with CH2Cl2 (3 ¥ 25 mL). The combined extracts
were washed with iced saturated aqueous NaHCO3 (20 mL),
dried (MgSO4), and concentrated. In the case of the mixture of
thioureido derivatives 32 and 33 the reaction was deacetylated by
theZemplenmethod. The resulting residuewas puriﬁed by column
chromatography using the eluent indicated in each case.
(4R)-4-[(4¢R)-3¢-O-Acetyl-1¢,2¢-O-isopropylidene-b-L-threofu-
ranos-4¢-yl]-2-butylamino-2-thiazoline (34). Column chromatog-
raphy, eluent 1 : 4 acetone–cyclohexane, recovering 35% of the
starting material. Yield: 185 mg (60%). [a]D -45.4 (c 1.0, CH2Cl2).
Rf 0.76 (1 : 2 acetone–cyclohexane, 2 elutions). IR (KBr) nmax 3383,
2931, 1747, 1624, 1374, 1078 cm-1. 1H NMR (500 MHz, CDCl3)
d 5.87 (d, 1 H, J1,2 = 3.8 Hz, H-1), 5.23 (d, 1 H, J3,4 = 3.0 Hz,
H-3), 4.48 (d, 1 H, H-2), 4.41 (m, 1 H, H-5), 4.13 (dd, 1 H, J4,5 =
9.2 Hz, H-4), 3.45 (dd, 1 H, J6a,6b = 11.0 Hz, J5,6a = 7.3 Hz, H-6a),
3.39 (dd, 1 H, J5,6b = 5.1 Hz, H-6b), 3.20 (t, 2 H, 3JH,H = 7.3 Hz,
CH2N), 2.08 (s, 3 H, MeCO), 1.49 (m, 2 H, CH2CH2N), 1.48, 1.28
(2 s, 6 H, CMe2), 1.33 (m, 2 H, CH2CH3), 0.87 (t, 3 H, 3JH,H =
7.4 Hz, CH3). 13C NMR (125.7 MHz, CDCl3) d 169.8 (CO), 163.0
(CN), 112.1 (CMe2), 104.9 (C-1), 83.5 (C-2), 80.0 (C-4), 76.5 (C-3),
69.9 (C-5), 44.9 (CH2N), 37.6 (C-6), 31.9 (CH2CH2N), 26.7, 26.2
(CMe2), 21.0 (MeCO), 20.0 (CH2CH3), 13.7 (CH3). FABMS: m/z
359 (100, [M + H]+). Anal. Calcd for C16H26N2O5S: C, 53.61; H,
7.31; N, 7.82. Found: C, 53.56; H, 7.33; N, 7.67%.
(4R)-4-[(4¢R)-3¢-O-Acetyl-1¢,2¢-O-isopropylidene-b-L-threofu-
ranos-4¢-yl]-2-(2,3,4,6-tetra-O-acetyl-b-D-glycopyranosyl)amino-
2-thiazoline (35). Column chromatography, eluent 1 : 1 EtOAc–
petroleum ether. Yield: 468 mg (86%). [a]D -13.2 (c 1.0, CH2Cl2).
Rf 0.59 (2 : 1 EtOAc-petroleum ether). IR (KBr) nmax 3462, 2942,
1749, 1631, 1374, 1036 cm-1. 1H NMR (300 MHz, CDCl3) d 5.92
(d, 1 H, J1,2 = 3.7 Hz, H-1), 5.31 (d, 1 H, J3,4 = 3.0 Hz, H-3), 5.30 (t,
1 H, J2¢,3¢ = J3¢,4¢ = 9.5 Hz, H-3¢), 5.07 (t, 1 H, J4¢,5¢ = 9.5 Hz, H-4¢),
5.02 (d, 1 H, J1¢,2¢ = 9.5 Hz, H-1¢), 4.93 (t, 1 H, H-2¢), 4.49 (d, 1 H,
H-2), 4.37 (m, 1 H, H-5), 4.36 (dd, 1 H, J6¢a,6¢b = 12.5 Hz, J5¢,6¢a =
4.4 Hz, H-6¢a), 4.18 (dd, 1 H, J5¢,6¢b = 1.9 Hz, H-6¢b), 4.13 (dd,






























































1 H, J4,5 = 4.5 Hz, H-4), 3.76 (ddd, 1 H, H-5¢), 3.53 (dd, 1 H,
J6a,6b = 11.1 Hz, J5,6a = 7.3 Hz, H-6a), 3.45 (dd, 1 H, J5,6b = 5.0 Hz,
H-6b), 2.05, 2.03, 1.99, 1.96, 1.94 (s, 15 H, MeCO), 1.42, 1.23
(2 s, 6 H, CMe2). 13C NMR (75.5 MHz, CDCl3, 313 K) d 170.8,
170.0, 169.6, 169.5 (MeCO), 161.3 (CN), 112.2 (CMe2), 105.1 (C-
1), 83.5 (C-1¢, C-2), 79.9 (C-4), 75.9 (C-3), 73.2 (C-3¢), 73.0 (C-5¢),
70.7 (C-2¢), 69.6 (C-5), 68.2 (C-4¢), 61.8 (C-6¢), 37.7 (C-6), 26.7,
26.1 (CMe2), 21.4, 21.0, 20.7, 20.6 (MeCO). FABMS:m/z 655 (25,
[M + Na]+), 633 (100, [M + H]+). Anal. Calcd for C26H36N2O14S:
C, 49.36; H, 5.74; N, 4.43. Found: C, 49.16; H, 5.56; N, 4.36%.
(4R)-4-[(4¢R)-1¢,2¢-O-Isopropylidene-b-L-threofuranos-4¢-yl]-2-
phenylamino-2-thiazoline (36). Column chromatography, eluent
60 : 1→ 30 : 1 CH2Cl2–MeOH. Yield: 257 mg (67%). [a]D +23.1 (c
0.9, MeOH). Rf 0.30 (20 : 1 CH2Cl2–MeOH). IR (KBr) nmax 3324,
2929, 1629, 1588, 1370, 1070 cm-1. 1H NMR (300 MHz, CD3OD)
d 7.34–6.96 (m, 5 H, Ph), 5.89 (d, 1 H, J1,2 = 3.6 Hz, H-1), 4.52 (d,
1 H, H-2), 4.43 (m, 1 H, H-5), 4.18 (d, 1 H, J3,4 = 2.6 Hz, H-3),
4.08 (dd, 1 H, J4,5 = 9.0 Hz, H-4), 3.45 (dd, 1 H, J6a,6b = 11.0 Hz,
J5,6a = 7.2 Hz, H-6a), 3.35 (dd, 1 H, J5,6b = 5.3 Hz, H-6b), 1.44, 1.29
(2 s, 6 H, CMe2). 13C NMR (75.5 MHz, CD3OD) d 162.4 (CN),
144.5–121.0 (Ph), 112.8 (CMe2), 106.4 (C-1), 86.8 (C-2), 82.6 (C-
4), 75.6 (C-3), 69.5 (C-5), 35.9 (C-6), 27.1, 26.4 (CMe2). FABMS:
m/z 359 (45, [M + Na]+), 337 (100, [M + H]+). Anal. Calcd for




(46). Column chromatography, eluent 9 : 1 : 0 → 7 : 1 : 0 →
70 : 10 : 1→ 40 : 10 : 1CH2Cl2–MeOH–H2O, recovering 35%of the
startingmaterial.Yield: 344mg (70%). [a]D -9.1 (c 1.0,CH2Cl2).Rf
0.41 (70 : 10 : 1 CH2Cl2–MeOH–H2O). IR (KBr) nmax 3286, 2953,
1645, 1374, 1070 cm-1. 1H NMR (300 MHz, CDCl3) d 6.69 (bs,
1 H, NH), 5.96 (d, 1 H, J1,2 = 3.6 Hz, H-1), 4.57 (d, 1 H, H-2),
4.45 (m, 1 H, H-5), 4.29 (d, 1 H, J3,4 = 2.8 Hz, H-3), 4.11 (dd,
1 H, J4,5 = 8.0 Hz, H-4), 3.54 (dd, 1 H, J6a,6b = 11.0 Hz, J5,6a =
7.5 Hz, H-6a), 3.42 (dd, 1 H, J5,6b = 5.6 Hz, H-6b), 3.28 (m, 6
H, CH2NH, CH2NHCO), 2.62 (m, 2 H, CH2CH2NH), 2.54 (t,
4 H, 3JH,H = 5.4 Hz, CH2CONH), 2.22 (t, 4 H, 3JH,H = 7.4 Hz,
CH2CH2NHCO), 1.63 (m, 4 H, CH2CH2CONH), 1.48, 1.31 (2 s,
6 H, CMe2), 1.29 (m, 8 H, CH2), 0.88 (t, 6 H, 3JH,H = 6.8 Hz, CH3).
13C NMR (75.5 MHz, CDCl3) d 174.3 (CO), 163.0 (CN), 111.5
(CMe2), 105.3 (C-1), 85.3 (C-2), 81.7 (C-4), 75.1 (C-3), 68.2 (C-5),
54.6 (CH2CH2NHCO), 52.6 (CH2CH2NH), 43.1 (CH2NH), 37.6
(CH2NHCO), 37.0 (C-6), 36.5 (CH2CONH), 31.6 (CH2), 26.9,
26.2 (CMe2), 25.5 (CH2CH2CONH), 22.4 (CH2CH3), 14.0 (CH3).
FABMS:m/z 608 (75, [M+Na]+), 586 (90, [M+H]+). Anal. Calcd




mn chromatography, eluent 30 : 1→ 20 : 1 CH2Cl2–MeOH, recov-
ering 20% of the starting material. Yield: 319 mg (76%). [a]D -9.0
(c 1.0, CH2Cl2). Rf 0.47 (10 : 1 CH2Cl2–MeOH). IR (KBr) nmax
3356, 2971, 1697, 1367, 1076 cm-1. 1H NMR (500 MHz, CDCl3)
d 5.99 (d, 1 H, J1,2 = 3.7 Hz, H-1), 4.59 (d, 1 H, H-2), 4.58 (bs,
1 H, NH), 4.45 (m, 1 H, H-5), 4.28 (d, 1 H, J3,4 = 2.5 Hz, H-3),
4.12 (dd, 1 H, J4,5 = 8.1 Hz, H-4), 3.78 (bs, 1 H, OH), 3.56 (dd,
1 H, J6a,6b = 10.9 Hz, J5,6a = 7.4 Hz, H-6a), 3.41 (dd, 1 H, J5,6b =
5.5 Hz, H-6b), 3.25 (m, 2 H, CH2N), 3.13 (m, 2 H, CH2NHCO),
1.52, 1.35 (2 s, 6 H, CMe2), 1.56 (m, 2 H, CH2CH2N), 1.47 (s, 9
H, CMe3), 1.49 (m, 2 H, CH2CH2NHCO), 1.46 (s, 9 H, CMe3),
1.33 (m, 8 H, CH2). 13C NMR (75.5 MHz, CDCl3) d 164.3 (CN),
156.0 (CO), 111.5 (CMe2), 105.2 (C-1), 85.2 (C-2), 81.9 (C-4), 79.0
(CMe3), 75.3 (C-3), 70.5 (C-5), 45.3 (CH2N), 40.6 (CH2NHCO),
37.7 (C-6), 30.0, 29.7, 29.0 (CH2), 28.4 (CMe3), 26.9, 26.2 (CMe2),
26.7 (CH2). FABMS: m/z 510 (10, [M + Na]+), 488 (100, [M +
H]+). Anal. Calcd for C23H41N3O6S: C, 56.65; H, 8.47; N, 8.62.
Found: C, 56.25; H, 8.34; N, 8.45%.
(4R)-2-(4-tert-Butoxycarbonylamino)butylamino-4-[(4¢R)-1¢,2¢-
O-isopropylidene-b-L-threofuranos-4¢-yl]-2-thiazoline (48). Colu-
mn chromatography, eluent 20 : 1→ 10 : 1 CH2Cl2–MeOH. Yield:
291 mg (78%). [a]D -7.3 (c 1.0, CH2Cl2). Rf 0.46 (7 : 1 CH2Cl2–
MeOH). IR (KBr) nmax 3372, 2934, 1696, 1367, 1166 cm-1. 1H
NMR (300 MHz, CDCl3) d 5.93 (d, 1 H, J1,2 = 3.6 Hz, H-1), 4.79
(bs, 1 H, NH), 4.54 (d, 1 H, H-2), 4.42 (m, 1 H, H-5), 4.25 (bs,
2 H, OH, NH), 4.23 (d, 1 H, J3,4 = 2.5 Hz, H-3), 4.03 (dd, 1 H,
J4,5 = 8.4 Hz, H-4), 3.51 (dd, 1 H, J6a,6b = 10.9 Hz, J5,6a = 7.4 Hz,
H-6a), 3.39 (dd, 1 H, J5,6b = 4.9 Hz, H-6b), 3.24 (m, 2 H, CH2N),
3.11 (m, 2 H, CH2NHCO), 1.53 (m, 4 H, CH2), 1.48, 1.30 (2 s,
6 H, CMe2), 1.33 (s, 9 H, CMe3). 13C NMR (75.5 MHz, CDCl3)
d 164.6 (CN), 156.1 (CO), 111.5 (CMe2), 105.1 (C-1), 85.2 (C-2),
81.6 (C-4), 79.3 (CMe3), 74.9 (C-3), 69.8 (C-5), 44.9 (CH2N), 40.0
(CH2NHCO), 37.4 (C-6), 28.4 (CMe3), 27.3, 26.8 (CH2), 26.8, 26.1
(CMe2). FABMS: m/z 454 (50, [M + Na]+), 432 (100, [M + H]+).
Anal. Calcd for C19H33N3O6S: C, 52.88; H, 7.71; N, 9.74; S, 7.43.
Found: C, 52.66; H, 7.65; N, 9.48; S, 7.19%.
(4R)-2-(4-Adamantan-1-ylcarbonylamino)butylamino-4-[(4¢R)-
1¢,2¢-O-isopropylidene-b-L-threofuranos-4¢-yl]-2-thiazoline (49).
Column chromatography, eluent 20 : 1→ 15 : 1→ 7 : 1 CH2Cl2–
MeOH. Yield: 315 mg (74%). [a]D -6.0 (c 1.0, CH2Cl2). Rf 0.45
(7 : 1 CH2Cl2–MeOH). IR (KBr) nmax 3344, 2907, 1620, 1373,
1075 cm-1. 1H NMR (300 MHz, CDCl3) d 5.93 (d, 1 H, J1,2 =
3.6 Hz, H-1), 5.86 (t, 1 H, 3JNH,H = 5.5 Hz, NH), 4.52 (d, 1 H, H-2),
4.42 (m, 1 H, H-5), 4.24 (d, 1 H, J3,4 = 2.5 Hz, H-3), 4.05 (dd, 1 H,
J4,5 = 8.5 Hz, H-4), 3.51 (dd, 1 H, J6a,6b = 11.0 Hz, J5,6a = 7.4 Hz,
H-6a), 3.39 (dd, 1 H, J5,6b = 5.1 Hz, H-6b), 3.25 (m, 4 H, CH2N,
CH2NHCO), 2.02 (bs, 3 H, CH), 1.82 (m, 6 H, CCH2) 1.69(m,
6 H, CHCH2), 1.54 (m, 4 H, CH2), 1.47, 1.29 (2 s, 6 H, CMe2).
13C NMR (75.5 MHz, CDCl3) d 178.4 (CO), 165.0 (CN), 111.5
(CMe2), 105.2 (C-1), 85.3 (C-2), 81.6 (C-4), 74.9 (C-3), 69.2 (C-5),
45.1 (CH2N), 40.6 (CCONH), 39.3 (CH), 38.7 (CH2NHCO), 37.2
(C-6), 36.5 (CCH2), 28.1 (CHCH2), 27.1, 26.7 (CH2), 26.9, 26.2
(CMe2). FABMS: m/z 516 (90, [M + Na]+), 494 (100, [M + H]+).
Anal. Calcd for C25H39N3O5S: C, 60.82; H, 7.96; N, 8.51; S, 6.50.
Found: C, 60.63; H, 7.79; N, 8.37, S, 6.29%.
(4R)-2-(11-Azido-3,6,9-trioxaundecyl)amino-4-[(4¢R)-1¢,2¢-O-
isopropylidene-b-L-threofuranos-4¢-yl]-2-thiazoline (50). Column
chromatography, eluent 1 : 1→ 2 : 1 acetone–cyclohexane. Yield:
279 mg (70%). [a]D -7.6 (c 1.0, CH2Cl2). Rf 0.26 (1 : 1 acetone–
cyclohexane). IR (KBr) nmax 3379, 2930, 2107, 1620, 1075 cm-1.
1H NMR (300 MHz, CDCl3) d 5.97 (d, 1 H, J1,2 = 3.7 Hz, H-1),
4.57 (d, 1 H, H-2), 4.43 (m, 1 H, H-5), 4.25 (d, 1 H, J3,4 = 2.8 Hz,
H-3), 4.08 (dd, 1 H, J4,5 = 8.2 Hz, H-4), 3.65 (m, 12H, OCH2), 3.54
(dd, 1 H, J6a,6b = 10.9 Hz, J5,6a = 7.4 Hz, H-6a), 3.42(m, 5 H, H-6b,






























































CH2N3, CH2N), 1.50, 1.29 (2 s, 6 H, CMe2). 13C NMR (75.5MHz,
CDCl3) d 163.7 (CN), 111.4 (CMe2), 105.2 (C-1), 85.1 (C-2), 82.0
(C-4), 75.4 (C-3), 71.4, 71.1 (OCH2), 70.7 (C-5), 70.6, 70.0, 69.6
(OCH2), 50.7 (CH2N3), 44.6 (CH2N), 42.7 (CH2CH2N3), 37.9 (C-
6), 26.9, 26.2 (CMe2). FABMS: m/z 484 (65, [M + Na]+), 462 (80,
[M + H]+). Anal. Calcd for C18H31N5O7S: C, 46.84; H, 6.77; N,
15.17. Found: C, 46.65; H, 6.48; N, 14.99%.
(4R)-2-(11-Adamantan-1-ylcarbonylamino-3,6,9-trioxaunde-
cyl)amino-4-[(4¢R)-1¢,2¢-O-isopropylidene-b-L-threofuranos-4¢-yl]-
2-thiazoline (51). Column chromatography, eluent 20 : 1→ 7 : 1
CH2Cl2–MeOH. Yield: 385 mg (46%). [a]D -9.5 (c 1.0, CH2Cl2).
Rf 0.55 (7 : 1 CH2Cl2–MeOH). IR (KBr) nmax 3356, 2905, 1623,
1375, 1075 cm-1. 1H NMR (300 MHz, CDCl3) d 6.14 (bs, 1 H,
NH), 5.95 (d, 1 H, J1,2 = 3.6 Hz, H-1), 4.56 (d, 1 H, H-2), 4.43 (m,
1 H, H-5), 4.25 (d, 1 H, J3,4 = 2.8 Hz, H-3), 4.09 (dd, 1 H, J4,5 =
8.1 Hz, H-4), 3.63 (m, 12 H, OCH2), 3.57 (dd, 1 H, J6a,6b = 11.0 Hz,
J5,6a = 5.3 Hz, H-6a), 3.46 (m, 1 H, H-6b), 3.42 (m, 4 H, CH2N,
CH2NHCO), 2.02 (bs, 3 H, CH), 1.84 (m, 6 H, CCH2), 1.70 (m, 6
H,CH2), 1.48, 1.31 (2 s, 6H,CMe2). 13CNMR (75.5MHz, CDCl3)
d 178.0 (CO), 163.9 (CN), 111.3 (CMe2), 105.1 (C-1), 85.0 (C-2),
81.8 (C-4), 75.2 (C-3), 70.4, 70.3, 70.2, 70.0, 69.8 (OCH2), 69.2 (C-
5), 44.6 (CH2N), 40.4 (CCONH), 39.0 (CH), 38.9 (CH2NHCO),
37.5 (C-6), 36.4 (CCH2), 28.0 (CH2), 26.7, 26.0 (CMe2). FABMS:
m/z 620 (100, [M + Na]+), 598 (20, [M + H]+). Anal. Calcd for
C29H47N3O8S: C, 58.27; H, 7.93; N, 7.03. Found: C, 57.98; H, 7.77;
N, 6.81%.
General procedure for the synthesis of 5-N ,6-S-(N ¢-
iminomethylidene)-6-thionojirimycin derivatives 37–39 and 52–57.
To a solution of the corresponding 2-amino-2-thiazoline precursor
34 and 35 (0.39 mmol) in dry MeOH (3.5 mL), methanolic
NaMeO (1 m, 0.1 equiv per mol of acetate) was added. The
reaction mixture was stirred at room temperature for 30 min,
then neutralized with solid CO2, and concentrated. The resulting
deacetylated product was treated with TFA-H2O (9 : 1, 2.4 mL)
for 30 min, concentrated under reduced pressure, coevaporated
several timeswithwater, neutralizedwithAmberlite IRA-68 (OH-)
ion-exchange resin, and subjected to column chromatographywith
the eluent indicated in each case to obtain the isothioureas 16
and 17. An analogous TFA-catalyzed reaction starting from 36
afforded the phenyl derivative 18. The corresponding 2-amino-
2-thiazoline precursor 46–51 (0.13 mmol), after treatment with
TFA-H2O (9 : 1, 1mL) for 30min at 0 ◦Cfollowedby concentration
under reduced pressure, coevaporation several times with water,
neutralization with Amberlite IRA-68 (OH-) ion-exchange resin
and column chromatography with the eluent indicated in each
case afforded the corresponding isothioureas 52–57. Compounds
53 and 54 were obtained as the corresponding hydrochloride salts
by freeze-drying from a solution of hydrochloric acid (pH 5).
5-N ,6-S-(N ¢-Butyliminomethylidene)-6-thionojirimycin (37).
Column chromatography, eluent 70 : 10 : 1 → 40 : 10 : 1 CH2Cl2–
MeOH–H2O. Yield: 86 mg (80%). [a]D -22.9 (c 0.7, H2O). Rf 0.26
(40 : 10 : 1 CH2Cl2–MeOH–H2O). 1H NMR (500 MHz, D2O) d
5.52 (d, 1 H, J1,2 = 3.7 Hz, H-1), 3.75 (td, 1 H, J4,5 = J5,6b = 9.5 Hz,
J5,6a = 6.4 Hz, H-5), 3.71 (t, 1 H, J2,3 = J3,4 = 9.5 Hz, H-3), 3.55
(dd, 1 H, H-2), 3.45 (dd, 1 H, J6a,6b = 10.5 Hz, H-6a), 3.40 (t, 1 H,
H-4), 3.18 (m, 2 H, CH2N), 3.07 (dd, 1 H, H-6b), 1.52 (m, 2 H,
CH2CH2N), 1.30 (m, 2 H, CH2CH3), 0.87 (t, 3 H, 3JH,H = 7.4 Hz,
CH3). 13C NMR (125.7 MHz, D2O) d 162.9 (CN), 76.0 (C-1),
74.3 (C-4), 72.8 (C-3), 71.4 (C-2), 59.8 (C-5), 53.9 (CH2N), 32.0
(C-6), 30.4 (CH2CH2N), 19.8 (CH2CH3), 13.2 (CH3). FABMS:
m/z 299 (40, [M + Na]+), 277 (100, [M + H]+). Anal. Calcd for
C11H20N2O4S: C, 47.81; H, 7.29; N, 10.14. Found: C, 47.65; H,
7.14; N, 9.99%.
5-N ,6-S -(N ¢-b-D-Glucopyranosyliminomethylidene)-6-thiono-
jirimycin (38). Column chromatography, eluent 6 : 1 : 1→ 6 : 3 : 1
CH3CN–H2O–NH4OH. Yield: 104 mg (70%). [a]D -15.5 (c
0.97, H2O). Rf 0.39 (6 : 3 : 1 CH3CN–H2O–NH4OH). 1H NMR
(500 MHz, D2O) d 5.70 (d, 1 H, J1,2 = 3.8 Hz, H-1), 4.37 (d, 1
H, J1¢,2¢ = 8.3 Hz, H-1¢), 3.87 (m, 2 H, H-5, H-6¢a), 3.74 (t, 1 H,
J2,3 = J3,4 = 9.9 Hz, H-3), 3.72 (dd, 1 H, J6¢a,6¢b = 12.5 Hz, J5¢,6¢b =
5.4 Hz, H-6¢b), 3.60 (dd, 1 H, H-2), 3.52 (m, 3 H, H-6a, H-3¢,
H-5¢), 3.46 (t, 1 H, J4,5 = 9.9 Hz, H-4), 3.44 (t, 1 H, J3¢,4¢ = J4¢,5¢ =
9.9 Hz, H-4¢), 3.36 (t, 1 H, J2¢,3¢ = 8.3 Hz, H-2¢), 3.17 (t, 1 H, J6a,6b =
J5,6b = 10.3 Hz, H-6b). 13C NMR (125.7 MHz, D2O) d 168.2 (CN),
93.2 (C-1¢), 77.6 (C-5¢), 76.1 (C-3¢), 75.8 (C-1), 74.4 (C-2¢), 74.0
(C-4), 72.6 (C-3), 71.0 (C-2), 69.6 (C-4¢), 60.8 (C-6¢), 59.9 (C-5),
30.7 (C-6). FABMS: m/z 405 (15, [M + Na]+). Anal. Calcd for
C13H22N2O9S: C, 40.83; H, 5.80; N, 7.33. Found: C, 4.83; H, 5.83;
N, 7.32%.
5-N ,6-S-(N ¢-Phenyliminomethylidene)-6-thionojirimycin (39).
Column chromatography, eluent 80 : 10 : 1 → 40 : 10 : 1 CH2Cl2–
MeOH–H2O. Yield: 81 mg (70%). [a]D -38.0 (c 0.5, H2O). Rf 0.20
(9 : 1 CH2Cl2–MeOH). 1H NMR (500 MHz, CD3OD) d 7.22 (t,
2 H, Ph), 7.00 (t, 1 H, Ph), 6.88 (d, 2 H, Ph), 5.72 (d, 1 H, J1,2 =
3.7 Hz, H-1), 3.82 (td, 1 H, J4,5 = J5,6b = 9.5 Hz, J5,6a = 6.5 Hz,
H-5), 3.71 (t, 1 H, J2,3 = J3,4 = 9.5 Hz, H-3), 3.45 (dd, 1 H, H-2),
3.35 (dd, 1 H, J6a,6b = 10.9 Hz, H-6a), 3.29 (t, 1 H, H-4), 3.00
(dd, 1 H, H-6b). 13C NMR (125.7 MHz, CD3OD) d 162.3 (CN),
152.6–123.0 (Ph), 77.8 (C-1), 76.3 (C-4), 74.8 (C-3), 73.4 (C-2),
61.1 (C-5), 31.8 (C-6). FABMS: m/z 319 (75, [M + Na]+). Anal.
Calcd for C13H16N2O4S: C, 52.69; H, 5.44; N, 9.45. Found: C,
52.50; H, 5.13; N, 9.29%.
5-N ,6 -S - (N ¢(N ,N -Bis(2 - hexanamidoethyl)aminoethyl)imino -
methylidene)-6-thionojirimycin (52). Column chromatography,
eluent 60 : 10 : 1→ 40 : 10 : 1 CH2Cl2–MeOH–H2O. Yield: 64 mg
(90%). [a]D -15.5 (c 1.0, H2O). Rf 0.41 (40 : 10 : 1 CH2Cl2–MeOH–
H2O). 1HNMR (500MHz,D2O) d 5.62 (d, 1H, J1,2 = 3.8Hz,H-1),
3.85 (m, 1 H, H-5), 3.74 (t, 1 H, J2,3 = J3,4 = 9.5 Hz, H-3), 3.57 (dd,
1 H, H-2), 3.56 (dd, 1 H, J6a,6b = 10.5 Hz, J5,6a = 6.5 Hz, H-6a), 3.45
(m, 6 H, CH2NCS, CH2NHCO), 3.44 (t, 1 H, J4,5 = 9.5 Hz, H-4),
3.25 (m, 2 H, CH2NCS), 3.18 (m, 4 H, CH2CH2NHCO), 3.17 (t, 1
H, J5,6b = 10.5 Hz, H-6b), 2.16 (t, 4 H, 3JH,H = 7.5 Hz, CH2CONH),
1.47 (m, 4 H, CH2CH2CONH), 1.18 (m, 8 H, CH2), 0.76 (t, 6 H,
3JH,H = 7.0 Hz, CH3). 13C NMR (125.7 MHz, D2O) d 178.3 (CO),
162.9 (CN), 75.9 (C-1), 74.3 (C-4), 72.6 (C-3), 71.3 (C-2), 60.5 (C-
5), 54.4 (CH2CH2NCS), 54.0 (CH2CH2NHCO), 48.0 (CH2NCS),
35.7 (CH2NHCO), 35.6 (CH2CONH), 31.1 (C-6), 30.6 (CH2), 25.0
(CH2CH2CONH), 21.7 (CH2CH3), 13.2 (CH3). FABMS: m/z 568
(30, [M+Na]+), 546 (40, [M+H]+). Anal. Calcd for C25H47N5O6S:
C, 55.02; H, 8.68; N, 12.83. Found: C, 55.09; H, 8.66; N, 12.86%.
5-N ,6-S-(N ¢-8¢-Aminooctyliminomethylidene)-6-thionojirimycin
hydrochloride (53). Column chromatography, eluent 6 : 1 : 1
CH3CN–H2O–NH4OH. Yield: 41 mg (91%). [a]D -7.0 (c 1.0,
H2O). Rf 0.49 (6 : 3 : 1 CH3CN–H2O–NH4OH). 1H NMR






























































(500 MHz, D2O, 313 K) d 5.76 (d, 1 H, J1,2 = 4.0 Hz, H-1), 4.46
(m, 1 H, H-5), 3.92 (m, 2 H, H-3, H-6a), 3.78 (dd, 1 H, J2,3 =
9.5 Hz, H-2), 3.71 (t, 1 H, J3,4 = J4,5 = 9.5 Hz, H-4), 3.61 (t, 1 H,
J6a,6b = J5,6b = 10.0 Hz, H-6b), 3.57 (t, 2 H, 3JH,H = 7.0 Hz, CH2N),
3.12 (t, 2 H, 3JH,H = 7.5 Hz, CH2NH2), 1.79 (m, 4 H, CH2), 1.48
(m, 8 H, CH2). 13C NMR (125.7 MHz, D2O, 313 K) d 173.0 (CN),
76.6 (C-1), 73.3 (C-4), 71.9 (C-3), 70.8 (C-2), 63.6 (C-5), 49.2
(CH2N), 39.8 (CH2NH2), 31.4 (C-6), 28.2, 28.1, 28.0, 26.9, 27.8,
25.7 (CH2). FABMS: m/z 348 (30, [M + H]+). HRFABMS: m/z
348.194640; calcd. for C15H30N3O4S: 348.195704. Anal. Calcd for
C15H30ClN3O4S: C, 46.92; H, 7.88; N, 10.94; S, 8.35. Found: C,
46.57; H, 7.69; N, 10.61; S, 8.04%.
5-N ,6-S-(N ¢-4¢-Aminobutyliminomethylidene)-6-thionojirimycin
hydrochloride (54). Column chromatography, eluent 10 : 1 : 1→
6 : 1 : 1 → 6 : 3 : 1 CH3CN–H2O–NH4OH. Yield: 35 mg (82%).
[a]D -11.3 (c 1.0, H2O). Rf 0.22 (6 : 3 : 1 CH3CN–H2O–NH4OH).
1H NMR (500 MHz, D2O) d 5.61 (d, 1 H, J1,2 = 3.7 Hz, H-1),
4.32 (m, 1 H, H-5), 3.76 (m, 2 H, H-3, H-6a), 3.62 (dd, 1 H, J2,3 =
9.5 Hz, H-2), 3.56 (t, 1 H, J3,4 = J4, 5 = 9.6 Hz, H-4), 3.46 (m, 3
H, H-6b, CH2N), 3.00 (t, 2 H, 3JH,H = 7.1 Hz, CH2NH2), 1.73
(m, 4 H, CH2). 13C NMR (125.7 MHz, D2O) d 175.7 (CN), 79.0
(C-1), 75.7 (C-4), 74.2 (C-3), 73.1 (C-2), 66.0 (C-5), 50.6 (CH2N),
41.5 (CH2NH2), 33.9 (C-6), 27.7, 26.5 (CH2). FABMS: m/z 314
(40, [M + Na - HCl]+), 292 (90, [M + H - Cl]+). Anal. Calcd for
C11H22ClN3O4S: C, 40.30; H, 6.76; N, 12.82; S, 9.78. Found: C,
39.95; H, 6.47; N, 12.49; S, 9.41%.
5 -N ,6 -S - (N ¢ - 4¢ - (Adamantane -1 - carbonylamino)butylimino -
methylidene)-6-thionojirimycin (55). Column chromatography,
eluent 40 : 10 : 1 CH2Cl2–H2O–MeOH. Yield: 58 mg (99%). [a]D
-7.1 (c 1.0, H2O). Rf 0.28 (40 : 10 : 1 CH2Cl2–H2O–MeOH). 1H
NMR (500 MHz, D2O, 313 K) d 5.73 (d, 1 H, J1,2 = 3.7 Hz, H-1),
4.38 (m, 1H,H-5), 3.91 (t, 1 H, J2,3 = J3,4 = 9.5Hz, H-3), 3.87 (dd, 1
H, J6a,6b = 11.3Hz, J5,6a = 7.5Hz, H-6a), 3.74 (dd, 1H, J2,3 = 9.5Hz,
H-2), 3.67 (t, 1 H, J4,5 = 9.5 Hz, H-4), 3.53 (m, 3 H, H-6b, CH2N),
3.33 (t, 2 H, 3JH,H = 6.7 Hz, CH2NHCO), 2.14 (bs, 3 H, CH), 1.92
(m, 6 H, CCH2) 1.83 (m, 6 H, CHCH2), 1.67 (m, 2 H, CH2). 13C
NMR (125.7 MHz, D2O, 313 K) d 182.0 (CO), 173.0 (CN), 76.6
(C-1), 73.5 (C-4), 72.0 (C-3), 70.9 (C-2), 63.1 (C-5), 49.3 (CH2N),
40.8 (CCONH), 38.8 (CH), 38.6 (CH2NHCO), 36.1 (CCH2), 31.4
(C-6), 28.0 (CHCH2), 25.9, 25.6 (CH2). FABMS: m/z 476 (20,
[M + Na]+), 454 (10, [M + H]+). Anal. Calcd for C22H35ClN3O5S:
C, 58.25; H, 7.78; N, 9.26; S, 7.07. Found: C, 58.17; H, 7.66; N,
9.05; S, 6.84%.
5-N ,6-S-(N ¢-11-Azido-3,6,9-trioxaundecyliminomethylidene)-6-
thionojirimycin (56). Column chromatography, eluent 70 : 10 : 1
→ 40 : 10 : 1 CH2Cl2–MeOH–H2O. Yield: 43 mg (78%). [a]D -13.0
(c 1.0, H2O). Rf 0.57 (40 : 10 : 1 CH2Cl2–MeOH–H2O). 1H NMR
(500 MHz, D2O) d 5.55 (d, 1 H, J1,2 = 3.7 Hz, H-1), 3.73 (m, 14
H, H-3, H-5, OCH2), 3.54 (dd, 1 H, J2,3 = 9.8 Hz, H-2), 3.45 (m,
2 H, CH2N), 3.45 (dd, 1 H, J6a,6b = 10.7 Hz, J5,6a = 6.3 Hz, H-6a),
3.39 (t, 1 H, J4,5 = 9.7 Hz, H-4), 3.35 (m, 2 H, CH2N3), 3.05 (t, 1
H, J5,6b = 10.7 Hz, H-6b). 13C NMR (125.7 MHz, D2O) d 166.1
(CN), 78.3 (C-1), 77.0 (C-4), 75.3 (C-3), 73.9 (C-2), 73.4, 73.1,
72.1, 72.0, 71.8 (OCH2), 62.1 (C-5), 56.0 (CH2N3), 52.7 (CH2N),
45.7 (CH2CH2N3), 33.1 (C-1). FABMS: m/z 444 (15, [M +
Na]+). HRFABMS: m/z 444.154344; calcd. for C15H27N5O7NaS:
444.152890. Anal. Calcd for C15H27N5O7S: C, 42.75; H, 6.46; N,
16.62; S, 7.61. Found: C, 42.51; H, 6.55; N, 16.46; S, 7.39%.
5-N ,6-S-(N ¢-11-Adamantane-1-carbonylamino-3,6,9-trioxaun-
decyliminomethylidene)-6-thionojirimycin (57). Column chro-
matography, eluent 80 : 10 : 1 → 40 : 10 : 1 CH2Cl2–H2O–
MeOH. Yield: 72 mg (99%). [a]D -6.2 (c 1.0, H2O). Rf 0.51
(40 : 10 : 1 CH2Cl2–H2O–MeOH). 1H NMR (500 MHz, D2O, 313
K) d 5.76 (d, 1 H, J1,2 = 3.7 Hz, H-1), 4.21 (m, 1 H, H-5), 3.90 (t,
1 H, J2,3 = J3,4 = 9.5 Hz, H-3), 3.84 (m, 12 H, OCH2), 3.79 (dd,
1 H, J6a,6b = 11.2 Hz, J5,6a = 7.1 Hz, H-6a), 3.73 (dd, 1 H, H-2),
3.67 (m, 2 H, CH2N), 3.63 (t, 1 H, J4,5 = 9.5 Hz, H-4), 3.52 (t,
2 H, 3JH,H = 5.5 Hz, CH2NHCO), 3.42 (t, 1 H, J5,6b = 11.2 Hz,
H-6b), 2.15 (bs, 3 H, CH), 1.94 (m, 6 H, CCH2) 1.85 (m, 6 H,
CH2). 13C NMR (125.7 MHz, D2O, 313 K) d 182.0 (CO), 163.0
(CN), 76.4 (C-1), 74.0 (C-4), 72.5 (C-3), 71.2 (C-2), 69.9, 69.8, 69.7,
69.3, 69.2 (OCH2), 61.9 (C-5), 51.1 (CH2N), 40.8 (CCONH), 39.1
(CH2NHCO), 38.7 (CH), 36.1 (CCH2), 31.2 (C-6), 27.9 (CH2).
FABMS: m/z 580 (100, [M + Na]+), 558 (5, [M + H]+). Anal.
Calcd for C26H43N3O8S: C, 55.99; H, 7.77; N, 7.53; S, 5.75. Found:
C, 55.68; H, 7.58; N, 7.32; S, 5.39%.
General procedure for the synthesis of 5-thioureido-a-D-
galactofuranose derivatives 58 and 59. A solution of 5-azido-
5-deoxy-1,2-O-isopropylidene-a-D-galactofuranose16 12 (350 mg,
1.43 mmol) in MeOH (7 mL) was hydrogenated at atmospheric
pressure for 1 h using 10% Pd/C (123 mg) as catalyst. The suspen-
sion was ﬁltered through Celite and concentrated. The resulting
residuewas dissolved in pyridine (8mL), Et3N (0.96mL, 6.9mmol,
5.6 eq) and the corresponding isothiocyanate (1.5 mmol, 1.2 eq)
were added and the mixture was stirred at room temperature for
18 h. Then, the solvent was removed under reduced pressure and
the resulting residue coevaporated several times with toluene and
puriﬁed by column chromatography using the eluent indicated in
each case.
5 - (N ¢ -Butylthioureido) -5 -deoxy-1,2 -O - isopropylidene -a -D -
galactofuranose (58). Column chromatography, eluent 20 : 1
CH2Cl2–MeOH. Yield: 344 mg (72%). [a]D +21.9 (c 1.0, CH2Cl2).
Rf 0.46 (10 : 1 CH2Cl2–MeOH). IR (KBr) nmax 3356, 2933, 1375,
1066 cm-1. UV (CH2Cl2) 250 nm (emM 15.7). 1H NMR (300 MHz,
CDCl3, 313 K) d 6.59 (bs, 2 H, NH), 5.80 (d, 1 H, J1,2 = 4.4 Hz, H-
1), 4.69 (m, 1 H, H-5), 4.66 (dd, 1 H, J2,3 = 2.8 Hz, H-2), 4.23 (dd,
1 H, J3,4 = 6.6 Hz, H-3), 3.96 (m, 1 H, H-4), 3.95 (dd, 1 H, J6a,6b =
11.8 Hz, J5,6a = 3.6 Hz, H-6a), 3.83 (dd, 1 H, J5,6b = 4.4 Hz, H-6b),
3.42 (m, 2 H, CH2N), 1.62 (m, 2 H, CH2CH2N), 1.52, 1.39 (2 s, 6
H, CMe2), 1.40 (m, 2 H, CH2CH3), 0.96 (t, 3 H, 3JH,H = 7.3 Hz,
CH3). 13C NMR (75.5 MHz, CDCl3, 313 K) d 182.5 (CS), 113.4
(CMe2), 104.6 (C-1), 86.6 (C-2), 77.2 (C-4), 75.8 (C-3), 63.9 (C-
6), 55.0 (C-5), 44.2 (CH2N), 30.8 (CH2CH2N), 27.7, 27.0 (CMe2),
20.0 (CH2CH3), 13.6 (CH3). FABMS: m/z 357 (52, [M + Na]+),
335 (100, [M + H]+). Anal. Calcd for C14H26N2O5S: C, 50.28; H,
7.84; N, 8.38. Found: C, 50.14; H, 7.63; N, 8.25%.
5-Deoxy-1,2-O - isopropylidene-5-(N ¢-phenylthioureido)-a-D-
galactofuranose (59). Column chromatography, eluent 40 : 1→
20 : 1 CH2Cl2–MeOH. Yield: 350 mg (69%). [a]D +4.0 (c 0.53,
CH2Cl2). Rf 0.28 (20 : 1 CH2Cl2–MeOH). UV (CH2Cl2) 264 nm
(emM 12.7). IR (KBr) nmax 3370, 2929, 1383, 1064 cm-1. 1H NMR
(300 MHz, CDCl3, 313 K) d 8.10 (bs, 1 H, N¢H), 7.46–7.24 (m, 5
H, Ph), 6.92 (d, 1H, J5,NH = 7.7Hz, NH), 5.71 (d, 1H, J1,2 = 4.4Hz,






























































H-1), 4.93 (m, 1 H, H-5), 4.64 (dd, 1 H, J2,3 = 3.1 Hz, H-2), 4.21
(dd, 1 H, J3,4 = 7.7 Hz, H-3), 3.96 (dd, 1 H, J6a,6b = 11.8 Hz, J5,6a =
3.0 Hz, H-6a), 3.85 (m, 2 H, H-6b, H-4), 2.67, 1.84 (2 bs, 2 H,
OH), 1.35, 1.27 (2 s, 6 H, CMe2). 13C NMR (125.7 MHz, CDCl3,
313 K) d 181.3 (CS), 136.1–124.9 (Ph), 114.1 (CMe2), 104.3 (C-1),
86.9 (C-2), 84.7 (C-4), 75.8 (C-3), 63.6 (C-6), 55.4 (C-5), 27.7, 27.0
(CMe2). FABMS: m/z 377 (100, [M + Na]+), 355 (15, [M + H]+).
Anal. Calcd for C16H22N2O5S: C, 54.22; H, 6.26; N, 7.90. Found:
C, 54.21; H, 5.98; N, 7.75%.
General procedure for the synthesis of (4S)-4-(L-threofuranos-
4¢-yl)-2-amino-2-thiazoline derivatives 60 and 61. The 2-amino-
2-thiazolines 60 and 61 were prepared from the corresponding
thioureido derivatives 58 and 59 following the general procedure
above described.
(4S)-2-Butylamino-4-[(4¢S)-1¢,2¢-O-isopropylidene-b-L-threofur-
anos-4¢-yl]-2-thiazoline (60). Column chromatography, eluent
80 : 10 : 1 CH2Cl2–MeOH–H2O. Yield: 163mg (60%). [a]D -29.6 (c
1.0, CH2Cl2). Rf 0.50 (70 : 10 : 1 CH2Cl2–MeOH–H2O). IR (KBr)
nmax 3361, 2924, 1615, 1375, 1063 cm-1. 1H NMR (300 MHz,
CDCl3) d 5.82 (d, 1 H, J1,2 = 3.8 Hz, H-1), 4.87 (bs, 1 H, NH),
4.56 (dd, 1 H, J2,3 = 1.3 Hz, H-2), 4.53 (m, 1 H, H-5), 4.25 (dd,
1 H, J3,4 = 5.2 Hz, H-3), 4.06 (t, 1 H, J4,5 = 5.2 Hz, H-4), 3.41
(d, 2 H, J5,6 = 7.8 Hz, H-6), 3.21 (m, 2 H, CH2N), 1.54 (m, 2 H,
CH2CH2N), 1.51, 1.24 (2 s, 6 H, CMe2), 1.35 (m, 2 H, CH2CH3),
0.91 (t, 3 H, 3JH,H = 7.3 Hz, CH3). 13C NMR (75.5 MHz, CDCl3) d
166.2 (CN), 113.4 (CMe2), 104.6 (C-1), 87.6 (C-2), 86.6 (C-4), 74.8
(C-3), 68.7 (C-5), 46.0 (CH2N), 34.0 (C-6), 31.6 (CH2CH2N), 27.4,
26.5 (CMe2), 19.8 (CH2CH3), 13.5 (CH3). FABMS: m/z 339 (30,
[M + Na]+), 317 (100, [M + H]+). Anal. Calcd for C14H24N2O4S:
C, 53.14; H, 7.65; N, 8.85. Found: C, 53.16; H, 7.56; N, 8.78%.
(4S)-4-[(4¢S)-1¢,2¢-O-Isopropylidene-b-L-threofuranos-4¢-yl]-2-
phenylamino-2-thiazoline (61). Column chromatography, eluent
50 : 1 → 20 : 1 CH2Cl2–MeOH. Yield: 150 mg (52%). [a]D -86.3
(c 1.0, CH2Cl2). Rf 0.30 (20 : 1 CH2Cl2–MeOH). IR (KBr) nmax
3361, 2962, 1621, 1375, 1015 cm-1. 1H NMR (300 MHz, CD3OD)
d 7.29–6.99 (m, 5 H, Ph), 5.90 (d, 1 H, J1,2 = 3.9 Hz, H-1), 4.56
(dd, 1 H, J2,3 = 0.75 Hz, H-2), 4.36 (m, 1 H, H-5), 4.22 (dd, 1 H,
J3,4 = 3.3 Hz, H-3), 3.94 (dd, 1 H, J4,5 = 8.1 Hz, H-4), 3.43 (dd,
1 H, J6a,6b = 11.0 Hz, J5,6a = 7.5 Hz, H-6a), 3.19 (dd, 1 H, J5,6b =
6.8 Hz, H-6b), 1.51, 1.33 (2 s, 6 H, CMe2). 13C NMR (75.5 MHz,
CD3OD) d 163.0 (CN), 147.7-122.0 (Ph), 114.1 (CMe2), 106.6 (C-
1), 89.5 (C-2), 88.9 (C-4), 77.1 (C-3), 66.6 (C-5), 33.3 (C-6), 27.5,
26.5 (CMe2). FABMS: m/z 359 (50, [M + Na]+), 337 (100, [M +
H]+). Anal. Calcd for C16H20N2O4S: C, 57.12; H, 5.99; N, 8.33.
Found: C, 56.93; H, 5.75; N, 8.21%.
Synthesis of 5-N ,6-S-(N ¢-iminomethylidene)-6-thiogalactono-
jirimycin derivatives 62 and 63. The isothioureas 60 and 61 were
prepared from the corresponding 2-amino-2-thiazoline precursor
(60 and 61) following the method B in general procedure above
described.
5-N ,6-S -(N ¢-Butyliminomethylidene)-6-thiogalactonojirimycin
(62). Column chromatography, eluent 60 : 10 : 1 → 40 : 10 : 1
CH2Cl2–MeOH–H2O. Yield: 31 mg (86%). [a]D -5.5 (c 0.6, H2O).
[a]546 -7.3 (c 0.6, H2O). Rf 0.21 (40 : 10 : 1 CH2Cl2–MeOH–H2O).
1H NMR (500 MHz, D2O) d 5.61 (d, 1 H, J1,2 = 3.2 Hz, H-1),
4.51 (t, 1 H, J5,6 = 9.0 Hz, H-5), 4.05 (bs, 1 H, H-4), 3.93 (dd, 1 H,
J2,3 = 10.2 Hz, J3,4 = 1.8 Hz, H-3), 3.83 (dd, 1 H, H-2), 3.49 (d, 2
H, H-6a, H-6b), 3.34 (t, 2 H, 3JH,H = 6.8 Hz, CH2N), 1.61 (m, 2 H,
CH2CH2N), 1.33 (m, 2 H, CH2CH3), 0.89 (t, 3 H, 3JH,H = 7.3 Hz,
CH3). 13C NMR (125.7 MHz, D2O) d 170.4 (CN), 76.0 (C-1),
69.1 (C-3), 68.9 (C-4), 67.4 (C-3), 61.8 (C-5), 50.0 (CH2N), 30.6
(CH2CH2N), 27.4 (C-6), 19.3 (CH2CH3), 12.9 (CH3). FABMS:
m/z 299 (55, [M + Na]+), 277 (100, [M + H]+). Anal. Calcd for
C11H20N2O4S: C, 47.81; H, 7.29; N, 10.14. Found: C, 47.69; H,
7.17; N, 9.94%.
5-N ,6-S-(N ¢-Phenyliminomethylidene)-6-thiogalactonojirimycin
(63). Column chromatography, eluent 80 : 10 : 1 CH2Cl2–
MeOH–H2O. Yield: 23 mg (60%). [a]D -25.5 (c 0.5, H2O). Rf 0.55
(40 : 10 : 1 CH2Cl2–MeOH–H2O). 1H NMR (500 MHz, D2O) d
7.38–7.01 (m, 5 H, Ph), 5.74 (bs, 1 H, H-1), 4.23 (bt, 1 H, J5,6a =
J5,6b = 9.0 Hz, 6.5 Hz, H-5), 4.04 (bs, 1 H, H-4), 3.95 (bd, 1 H,
J2,3 = 9.3 Hz, H-3), 3.88 (bd, 1 H, H-2), 3.30 (bt, 1 H, J6a,6b =
9.0 Hz, H-6a), 3.20 (bt, 1 H, H-6b). 13C NMR (125.7 MHz, D2O)
d 173.9 (CN), 149.0–122.5 (Ph), 75.8 (C-1), 69.7 (C-3), 68.8 (C-4),
67.9 (C-2), 59.2 (C-5), 26.7 (C-6). FABMS: m/z 322 (100, [M +
Na + 3H]+), 297 (10, [M + H]+). Anal. Calcd for C13H16N2O4S: C,
52.69; H, 5.44; N, 9.45. Found: C, 52.69; H, 5.38; N, 9.38%.
General procedure for the synthesis of 5,6-di-N-(N ¢-imino-
methylidene)-a-D-(galacto)glucofuranose derivatives 66–69. A so-
lution of 641 or 652 (0.73 mmol) and the corresponding amine
(1.5 eq) in DMF (15 mL) was heated at 70 ◦C under Ar for 18 h
and concentrated. The resulting residue was puriﬁed by column
chromatography using the eluent indicated in each case. Except-
ing 66, the 5,6-di-N-(N¢-iminomethylidene)-a-D-glycofuranose
derivatives were obtained as the corresponding hydrochloride salt
by freeze-drying from a solution of hydrochloric acid (pH 5).
5,6-Diamino-5,6-di-N-(N ¢-butyliminomethylidene)-5,6-dideoxy-
1,2-O-isopropylidene-a-D-glucofuranose (66). Column chro-
matography, eluent 80 : 10 : 1 CH2Cl2–MeOH–H2O. Yield: 166 mg
(76%). [a]D -45.4 (c 1.0, CH2Cl2). Rf 0.49 (70 : 10 : 1 CH2Cl2–
MeOH–H2O). IR (KBr) nmax 3284, 2959, 1673, 1375, 1075 cm-1.
1H NMR (300 MHz, CD3OD) d 5.95 (d, 1 H, J1,2 = 3.6 Hz, H-1),
4.53 (d, 1 H, H-2), 4.35 (m, 1 H, H-5), 4.26 (dd, 1 H, J4,5 = 4.9 Hz,
J3,4 = 3.0 Hz, H-4), 4.20 (d, 1 H, H-3), 3.82 (dd, 1 H, J6a,6b =
9.9 Hz, J5,6a = 7.0 Hz, H-6a), 3.78 (t, 1 H, J5,6b = 9.9 Hz, H-6b),
3.23 (t, 2 H, 3JH,H = 7.0 Hz, CH2N), 1.60 (m, 2 H, CH2CH2N),
1.48, 1.32 (2 s, 6 H, CMe2), 1.42 (m, 2 H, CH2CH3), 0.98 (t, 3
H, 3JH,H = 7.3 Hz, CH3). 13C NMR (75.5 MHz, CD3OD) d 160.2
(CN), 113.0 (CMe2), 106.6 (C-1), 86.8 (C-2), 82.5 (C-4), 75.4
(C-3), 55.6 (C-5), 46.1 (C-6), 43.6 (CH2N), 32.2 (CH2CH2N),
27.2, 26.4 (CMe2), 20.8 (CH2CH3), 13.9 (CH3). FABMS: m/z 300
(100, [M + H]+). Anal. Calcd for C14H25N3O4: C, 56.17; H, 8.42;
N, 14.04. Found: C, 55.96; H, 8.65; N, 13.94%.
5,6-Diamino-5,6-di-N -(N ¢-benzyliminomethylidene)-5,6-dideo-
xy-1,2-O-isopropylidene-a-D-glucofuranose hydrochloride (67).
Column chromatography, eluent 90 : 10 : 1 → 40 : 10 : 1 CH2Cl2–
MeOH–H2O. Yield: 175 mg (65%). [a]D -15.4 (c 1.0, CH2Cl2). Rf
0.63 (40 : 10 : 1 CH2Cl2–MeOH–H2O). IR (KBr) nmax 3292, 2985,
1669, 1378, 1074 cm-1. 1H NMR (300 MHz, CD3OD) d 7.43–7.33
(m, 5 H, Ph), 5.95 (d, 1 H, J1,2 = 3.6 Hz, H-1), 4.52 (d, 1 H, H-2),
4.45 (s, 2 H, CH2Ph), 4.38 (ddd, 1 H, J5,6b = 10.1 Hz, J5,6a = 6.7 Hz,
J4,5 = 4.8 Hz, H-5), 4.26 (dd, 1 H, J3,4 = 3.0 Hz, H-4), 4.17 (d,
1 H, H-3), 3.85 (dd, 1 H, J6a,6b = 10.2 Hz, H-6a), 3.80 (t, 1 H,






























































H-6b), 1.48, 1.32 (2 s, 6 H, CMe2). 13C NMR (75.5MHz, CD3OD)
d 160.3 (CN), 137.5–128.4 (Ph), 113.0 (CMe2), 106.6 (C-1), 86.9
(C-2), 82.5 (C-4), 75.5 (C-3), 55.8 (C-5), 47.3 (CH2Ph), 46.2 (C-6),
27.2, 26.4 (CMe2). FABMS: m/z 334 (100, [M + H - Cl]+). Anal.
Calcd for C17H24ClN3O4: C, 55.21; H, 6.54; N, 11.36. Found: C,
55.15; H, 6.56; N, 11.29%.
5,6-Diamino-5,6-di-N-(N ¢-butyliminomethylidene)-5,6-dideoxy-
1,2-O-isopropylidene-a-D-galactofuranose hydrochloride (68).
Column chromatography, eluent 100 : 10 : 1→ 80 : 10 : 1 CH2Cl2–
MeOH–H2O. Yield: 297 mg (75%). [a]D -31.6 (c 1.0, MeOH). Rf
0.49 (40 : 10 : 1 CH2Cl2–MeOH–H2O). IR (KBr) nmax 3285, 2954,
1673, 1379, 1068 cm-1. 1H NMR (300 MHz, CD3OD) d 5.93 (d,
1 H, J1,2 = 3.7 Hz, H-1), 4.57 (d, 1 H, H-2), 4.31 (m, 1 H, H-5),
4.07 (d, 1 H, J3,4 = 2.6 Hz, H-3), 3.89 (dd, 1 H, J4,5 = 8.9 Hz, H-4),
3.87 (t, 1 H, J6a,6b = J5,6a = 10.0 Hz, H-6a), 3.55 (dd, 1 H, J5,6b =
5.9 Hz, H-6b), 3.24 (t, 2 H, 3JH,H = 7.0 Hz, CH2N), 1.60 (m, 2 H,
CH2CH2N), 1.53, 1.34 (2 s, 6 H, CMe2), 1.41 (m, 2 H, CH2CH3),
0.98 (t, 3 H, 3JH,H = 7.3 Hz, CH3). 13C NMR (75.5 MHz, CD3OD)
d 160.5 (CN), 114.0 (CMe2), 107.1 (C-1), 89.9 (C-4), 88.4 (C-2),
76.3 (C-3), 58.2 (C-5), 46.1 (C-6), 43.7 (CH2N), 32.2 (CH2CH2N),
27.4, 26.2 (CMe2), 20.7 (CH2CH3), 13.9 (CH3). FABMS: m/z 300
(100, [M + H - Cl]+). Anal. Calcd for C14H26ClN3O4: C, 50.07; H,
7.80; N, 12.51. Found: C, 50.1; H, 8.03; N, 12.30%.
5,6-Diamino-5,6-di-N -(N ¢-benzyliminomethylidene)-5,6-dideo-
xy-1,2-O-isopropylidene-a-D-galactofuranose hydrochloride (69).
Column chromatography, eluent 100 : 10 : 1→ 70 : 10 : 1 CH2Cl2–
MeOH–H2O. Yield: 179 mg (55%). [a]D -62.0 (c 1.0, MeOH). Rf
0.43 (40 : 10 : 1 CH2Cl2–MeOH–H2O). IR (KBr) nmax 3389, 2931,
1674, 1367, 1067 cm-1. 1H NMR (500 MHz, CD3OD) d 7.41–7.33
(m, 5 H, Ph), 5.94 (d, 1 H, J1,2 = 3.8 Hz, H-1), 4.58 (d, 1 H, H-
2), 4.47 (s, 2 H, CH2Ph), 4.36 (m, 1 H, H-5), 4.09 (d, 1 H, J3,4 =
2.6 Hz, H-3), 3.91 (dd, 1 H, J4,5 = 9.1 Hz, H-4), 3.90 (t, 1 H, J6a,6b =
J5,6a = 9.9 Hz, H-6a), 3.58 (dd, 1 H, J5,6b = 5.9 Hz, H-6b), 1.53,
1.34 (2 s, 6 H, CMe2). 13C NMR (125.7 MHz, CD3OD) d 160.5
(CN), 137.5–128.4 (Ph), 114.0 (CMe2), 107.1 (C-1), 89.9 (C-4),
88.4 (C-2), 76.3 (C-3), 58.3 (C-5), 47.3 (CH2Ph), 46.2 (C-6), 27.4,
26.2 (CMe2). FABMS: m/z 334 (100, [M + HCl]+). HRFABMS:
m/z 334.176627; calcd. for C17H24N3O4: 334.176682. Anal. Calcd
for C17H26ClN3O5: C, 52.64; H, 6.76; N, 10.83. Found: C, 52.64;
H, 6.64; N, 10.71%.
General procedure for the synthesis of 6-amino-6-deoxy-5,6-
di-N-(N ¢-iminomethylidene)(galacto)nojirimycin derivatives 70–
73. The corresponding 2-amino-2-imidazoline precursor 66–
69 (0.41 mmol) was treated with TFA-H2O (9 : 1, 1.7 mL) for
1 h at 0 ◦C, concentrated under reduced pressure, coevaporated
several times with water, treated with NaOH 0.1 N until pH 8, and
subjected to column chromatography with the eluent indicated
in each case. The corresponding guanidines were isolated as
hydrochloride salt, puriﬁed byGPC (SephadexG-10, 1 : 1MeOH–
H2O), concentrated, and freeze-dried.
6-Amino-5,6-di-N -(N ¢-butyliminomethylidene)-6-deoxynojiri-
mycin hydrochloride (70). Column chromatography, eluent
4 : 1 : 1 CH3CN–H2O–NH4OH. Yield: 103 mg (80%). [a]D +7.7
(c 0.8, H2O). Rf 0.53 (6 : 3 : 1 CH3CN–H2O–AcOH). 1H NMR
(300 MHz, D2O) d 5.42 (d, 1 H, J1,2 = 3.7 Hz, H-1), 3.95 (m, 1
H, H-5), 3.86 (t, 1 H, J6a,6b = J5,6a = 9.5 Hz, H-6a), 3.72 (t, 1 H,
J2,3 = J3,8 = 9.5 Hz, H-3), 3.60 (dd, 1 H, H-2), 3.52 (t, 1 H, J4,5 =
9.5 Hz, H-4), 3.50 (t, 1 H, J5,6b = 9.5 Hz, H-6b), 3.23 (t, 2 H, 3JH,H =
7.1Hz, CH2N), 1.57 (m, 2H, CH2CH2N), 1.35 (m, 2H, CH2CH3),
0.92 (t, 3 H, 3JH,H = 7.3 Hz, CH3). 13C NMR (75.5 MHz, D2O)
d 156.6 (CN), 74.6 (C-1), 73.5 (C-4), 72.6 (C-3), 71.7 (C-2), 56.3
(C-5), 46.3 (C-6), 42.8 (CH2N), 30.3 (CH2CH2N), 19.3 (CH2CH3),
12.9 (CH3). FABMS: m/z 260 (100, [M + Cl]+). Anal. Calcd for
C11H24ClN3O5: C, 42.11; H, 7.71; N, 13.39. Found: C, 42.21; H,
7.81; N, 13.31%.
6-Amino-5,6-di-N -(N ¢-benzyliminomethylidene)-6-deoxynojiri-
mycin hydrochloride (71). Column chromatography, eluent
4 : 1 : 1 CH3CN–H2O–NH4OH. Yield: 93 mg (65%). [a]D +4.0
(c 1.0, H2O). Rf 0.29 (4 : 1 : 1 CH3CN–H2O–NH4OH). 1H NMR
(400 MHz, D2O) d 7.34 (m, 5 H, Ph), 5.40 (d, 1 H, J1,2 = 3.8 Hz,
H-1), 4.40 (s, 2 H, CH2Ph), 3.93 (m, 1 H, H-5), 3.76 (t, 1 H, J6a,6b =
J5,6a = 9.5 Hz, H-6a), 3.66 (t, 1 H, J2,3 = J3,4 = 9.5 Hz, H-3), 3.57
(dd, 1 H, H-2), 3.46 (t, 1 H, J4,5 = 9.5 Hz, H-4), 3.42 (dd, 1 H,
J5,6b = 9.5 Hz, H-6b). 13C NMR (75.5 MHz, D2O) d 156.5 (CN),
136.3-127.0 (Ph), 74.4 (C-1), 73.3 (C-4), 72.4 (C-3), 71.4 (C-2),
56.2 (C-5), 46.1 (C-6, CH2Ph). FABMS: m/z 294 (60, [M + Cl]+).
Anal. Calcd for C14H22ClN3O5: C, 48.35; H, 6.38; N, 12.08. Found:
C, 48.19; H, 6.20; N, 11.92%.
6-Amino-5,6-di-N -(N ¢-butyliminomethylidene)-6-deoxygalacto-
nojirimycin hydrochloride (72). Column chromatography, eluent
100 : 10 : 0.5 → 100 : 10 : 1 CH3CN–H2O–AcOH. Yield: 73 mg
(60%). [a]D +8.0 (c 1.0, H2O). Rf 0.61 (20 : 2 : 1 CH3CN–H2O–
AcOH). 1H NMR (500 MHz, D2O) d 5.40 (d, 1 H, J1,2 = 4.0 Hz,
H-1), 4.25 (t, 1 H, J5,6a = J5,6b = 9.7 Hz, H-5), 3.98 (m, 1 H, H-4),
3.82 (dd, 1 H, J2,3 = 9.8 Hz, J3,4 = 2.5 Hz, H-3), 3.74 (dd, 1 H,
H-2), 3.69 (t, 1 H, J6a,6b = 9.7 Hz, H-6a), 3.56 (t, 1 H, H-6b), 3.15
(t, 2 H, 3JH,H = 7.0 Hz, CH2N), 1.48 (m, 2 H, CH2CH2N), 1.26
(m, 2 H, CH2CH3), 0.81 (t, 3 H, 3JH,H = 7.3 Hz, CH3). 13C NMR
(125.7MHz,D2O) d 155.9 (CN), 74.0 (C-1), 69.2 (C-3), 68.1 (C-4),
67.8 (C-2), 55.7 (C-5), 42.7 (CH2N), 41.7 (C-6), 30.1 (CH2CH2N),
19.2 (CH2CH3), 12.9 (CH3). FABMS: m/z 260 (100, [M - Cl]+).
HRFABMS: m/z 260.160864; calcd. for C11H22N3O4: 260.161031.
Anal. Calcd for C11H22ClN3O4: C, 44.67; H, 7.50; N, 14.21. Found:
C, 44.29; H, 7.35; N, 13.93%.
6-Amino-5,6-di-N -(N ¢-benzyliminomethylidene)-6-deoxygalac-
tonojirimycin hydrochloride (73). Column chromatography, elu-
ent 50 : 5 : 1→ 20 : 2 : 1 CH3CN–H2O–AcOH. Yield: 92 mg (68%).
[a]D +7.0 (c 0.8, H2O). Rf 0.32 (20 : 2 : 1 CH3CN–H2O–AcOH).
1H NMR (300 MHz, D2O) d 7.39–7.27 (m, 5 H, Ph), 5.45(d, 1 H,
J1,2 = 3.8 Hz, H-1), 4.41 (s, 2 H, CH2Ph), 4.28 (td, 1 H, J5,6a = J5,6b =
9.8 Hz, J4,5 = 1.4 Hz, H-8a), 3.99 (dd, 1 H, J3,4 = 2.7 Hz, H-4),
3.84(dd, 1 H, J2,3 = 10.2 Hz, H-3), 3.77 (dd, 1 H, H-2), 3.68 (t, 1 H,
J6a,6b = 9.8 Hz, H-6a), 3.55 (t, 1 H, H-6b). 13C NMR (75.5 MHz,
D2O) d 156.7 (CN), 136.1–127.6 (Ph), 74.8 (C-1), 69.7 (C-3), 68.7
(C-4), 68.4 (C-2), 56.4 (C-5), 46.4 (CH2Ph), 42.5 (C-6). FABMS:
m/z 294 (100, [M - Cl]+). HRFABMS: m/z 294.144663; calcd. for
C14H20N3O4: 294.145381. Anal. Calcd for C14H22ClN3O5: C, 48.35;
H, 6.38; N, 12.08. Found: C, 48.02; H, 6.16; N, 11.76%.
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